US7514445B2 - Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) - Google Patents

Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) Download PDF

Info

Publication number
US7514445B2
US7514445B2 US10/493,452 US49345204A US7514445B2 US 7514445 B2 US7514445 B2 US 7514445B2 US 49345204 A US49345204 A US 49345204A US 7514445 B2 US7514445 B2 US 7514445B2
Authority
US
United States
Prior art keywords
alkyl
monocyclic
bicyclic
tricyclic
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US10/493,452
Other versions
US20050004125A1 (en
Inventor
Eddy Jean Edgard Freyne
Peter Jacobus Johannes Antonius Buijnsters
Marc Willems
Werner Constant Johan Embrechts
Christopher John Love
Paul Adriaan Jan Janssen
Paulus Joannes Lewi
Jan Heeres
Marc René De Jonge
Lucien Maria Henricus Koymans
Hendrik Maarten Vinkers
Koen Jeanne Alfons Van Aken
Gaston Stanislas Marcella Diels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of US20050004125A1 publication Critical patent/US20050004125A1/en
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUIJNSTERS, PETER J. J. A., DE JONGE, MARC R., DIELS, GASTON S. M., EMBRECHTS, WERNER C. J., FREYNE, EDDY J. E., HEERES, JAN, JANSSEN (DECEASED - BY HEIRS), PAUL A. J., KOYMANS, LUCIEN M. H., LEWI, PAULUS J., LOVE, CHRISTOPHER J., VAN AKEN, KOEN J. A., VINKERS, HENDRIK M., WILLEMS, MARC
Application granted granted Critical
Publication of US7514445B2 publication Critical patent/US7514445B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention concerns a novel group of heterocyclic derivatives, their use as a medicine, their use for the manufacture of a medicament for the treatment of diseases mediated through glycogen synthase kinase 3; processes for their preparation and pharmaceutical compositions comprising them.
  • WO 01/72745 describes 2-substituted 4-heteroaryl-pyrimidines useful in the treatment of proliferative disorders.
  • WO 98/41512 relates to substituted 2-anilinopyrimidines useful as protein kinase inhibitors.
  • WO 95/09851 describes pyrimidineamine derivatives useful in the treatment of tumour diseases.
  • WO 01/12621 describes inhibitors of c-JUN-N-terminal kinases and other protein kinases.
  • WO 01/60816 describes pyrimidine derivatives useful as kinase inhibitors.
  • WO 97/19065 discloses substituted 2-anilinopyrimidines useful as p56 lck , p59 fyn , ZAP-70 and protein kinase C inhibitors.
  • WO 91/18887 discloses diaminopyrimidine compounds as inhibitors of gastric acid secretion.
  • WO 99/50250 concerns HIV inhibiting aminopyrimidine derivatives.
  • U.S. Pat. No. 5,516,775 concerns the use of 2-anilinopyrimidines as protein kinase C inhibitors.
  • WO 95/09853 describes N-phenyl-2-pyrimidineamine derivatives for the treatment of tumor diseases.
  • WO 98/18782 concerns 2-pyrimidineamine derivatives as selective protein tyrosine kinase inhibitors.
  • EP 0,337,943 discloses N-phenyl-N-pyrimidin-2-yl derivatives having herbicidal plant growth regulating activity.
  • EP 0,164,204 concerns 2-aminopyrimidines which augment the immune respons.
  • EP 0,233,461 relates to 4,5,6-substituted 2-pyrimidineamines having anti-asthmatic activity.
  • WO 00/62778 describes cyclic protein tyrosine kinase inhibitors.
  • the present invention relates to compounds which are distinguishable from the prior art in structure, pharmacological activity, potency or selectivity.
  • the present invention concerns a compound of formula (I)
  • ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • the present invention also relates to the use of a compound for the manufacture of a medicament for the prevention or the treatment of diseases mediated through GSK3, said compound being a compound of formula (I′)
  • ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • C 1-3 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl;
  • C 1-4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the groups defined for C 1-3 alkyl and butyl;
  • C 1-6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C 1-4 alkyl and pentyl, hexyl, 2-methylbutyl and the like;
  • C 1-10 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for C 1-6 alkyl and heptyl, octyl, nony
  • a monocyclic, bicyclic or tricyclic saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, said ring system containing only single bonds
  • a monocyclic, bicyclic or tricyclic partially saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, and at least one double bond provided that the ring system is not an aromatic ring system
  • a monocyclic, bicyclic or tricyclic aromatic heterocycle represents an aromatic ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S.
  • monocyclic, bicyclic or tricyclic saturated carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[4,2,0]octanyl, cyclononanyl, cyclodecanyl, decahydronapthalenyl, tetradecahydroanthracenyl.
  • monocyclic, bicyclic or tricyclic partially saturated carbocycles are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclo-octenyl, bicyclo[4,2,0]octenyl, cyclononenyl, cyclodecenyl, octahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4,4a,9,9a,10-octahydro-anthracenyl.
  • monocyclic, bicyclic or tricyclic aromatic carbocycles are phenyl, naphthalenyl, anthracenyl.
  • monocyclic, bicyclic or tricyclic saturated heterocycles are tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, decahydroquinolinyl, octahydroindolyl.
  • monocyclic, bicyclic or tricyclic partially saturated heterocycles are pyrrolinyl, imidazolinyl, pyrazolinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolinyl and the like.
  • monocyclic, bicyclic or tricyclic aromatic heterocycles are azetyl, oxetylidenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl
  • 5-membered aromatic heterocycles are pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl.
  • ( ⁇ O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.
  • halo is generic to fluoro, chloro, bromo and iodo.
  • polyhalomethyl as a group or part of a group is defined as mono- or polyhalosubstituted methyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl;
  • polyhaloC 1-6 alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C 1-6 alkyl, for example, the groups defined in halomethyl, 1,1-difluoro-ethyl and the like.
  • more than one halogen atoms are attached to an alkyl group within the definition of polyhalomethyl or polyhaloC 1-6 alkyl, they may be the same or different.
  • heterocycle as in the definition of for instance R 4 , R 5 , R 6 , R 8 or R 15 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl also includes 2H-pyrrolyl.
  • the hereinabove-mentioned carbocycles may be attached to the remainder of the molecule of formula (I) or (I′) through any ring carbon as appropriate, if not otherwise specified.
  • the partially saturated bicyclic carbocycle is 1,2,3,4-tetrahydronaphthalenyl, it may be 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl and the like.
  • heterocycles may be attached to the remainder of the molecule of formula (I) or (I′) through any ring carbon or heteroatom as appropriate, if not otherwise specified.
  • aromatic monocyclic heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like.
  • salts of the compounds of formula (I) or (I′) are those wherein the counterion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) or (I′) are able to form.
  • the latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
  • hydrochloric, hydrobromic and the like sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.
  • the salt form can be converted by treatment with alkali into the free base form.
  • the compounds of formula (I) or (I′) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
  • primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • the salt form can be converted by treatment with acid into the free acid form.
  • addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) or (I′) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • quaternary amine as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) or (I′) are able to form by reaction between a basic nitrogen of a compound of formula (I) or (I′) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide.
  • Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates.
  • a quaternary amine has a positively charged nitrogen.
  • Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.
  • stereochemically isomeric forms as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I) or (I′), and their N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess.
  • chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) or (I′) and their N-oxides, salts, solvates or quaternary amines substantially free, i.e.
  • stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration.
  • Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond.
  • Stereochemically isomeric forms of the compounds of formula (I) or (I′) are obviously intended to be embraced within the scope of this invention.
  • N-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called N-oxide.
  • Particular compounds are those compounds of formula (I) or (I′) as defined hereinabove provided that the molecular mass of the compounds is at most 1000 u, in particular at most 800 u, more in particular at most 700 u (u stands for unified atomic mass unit and equals 1.66 ⁇ 10 ⁇ 27 kg).
  • Particular compounds are also those compounds of formula (I) or (I′) as defined hereinabove provided that when R 3 is hydrogen then X is other than —C( ⁇ O)—NR 1 —or —C( ⁇ S)—NR 1 —; and provided that when X is a direct bond and R 2 is hydrogen than R 3 is other than R 7 —C( ⁇ O)— with R 7 representing amino or mono- or di(C 1-6 alkyl)amino; and provided that when X is a direct bond and R 2 is hydrogen than R 21 is other than a heterocycle; and
  • R 3 is hydrogen then R 2 is other than a heterocycle.
  • Particular interesting compounds are those compounds of formula (I) or (I′) as defined hereinabove, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • R 4 is 4-pyridyl substituted in position 3;
  • R 3a is hydrogen, halo, C 1-6 alkyloxy or C 1-6 alkyl;
  • R 3b is as defined above for R 3 ;
  • R 4 is 4-pyridyl substituted in position 3;
  • R 3a is hydrogen, halo, C 1-6 alkyloxy or C 1-6 alkyl;
  • X—R 2 is as defined above;
  • R 3a is halo, cyano, C 1-4 alkyloxy, polyhaloC 1-4 alkyloxy, C 1-4 alkylthio, C 1-4 alkyl-S( ⁇ O)—, C 1-4 alkyl-S( ⁇ O) 2 —, C 1-4 alkyl, polyhaloC 1-4 alkyl, C 1-4 alkyloxycarbonyl, mono-or di(C 1-4 alkyl)aminocarbonyl, aminocarbonyl, polyhaloC 1-4 alkylthio;
  • R 3b is hydrogen, halo, cyano, nitro, C 1-4 alkyl, C 1-4 alkyloxy, polyhaloC 1-4 alkyl, C 1-4 alkyloxycarbonyl, C 1-4 alkylcarbonyl;
  • R 3c is hydrogen, halo or C 1-4 alkyl;
  • R 4 is 2-furanyl, 2-thienyl or 3-thienyl;
  • R 4 is pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, pyridazinyl, or imidazolyl, each of said rings optionally substituted with one or more substituents selected from halo, cyano, aminocarbonyl, —C( ⁇ O)—O—R 4 ′, —C( ⁇ O)—R 4 ′, —S( ⁇ O) 2 —NR 4 ′R 4 ′′, NR 4 ′R 4 ′′, —O—R 4 ′ or C 1-6 alkyl optionally substituted with fluoro wherein R 4′ and R 4′′ each independently represent hydrogen or C 1-6 alkyl optionally substituted with mono- or di(C 1-6 alkyl)amino; R 1 , R 3 and s are as defined hereinabove;
  • R 4 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 6-methyl-3-pyridyl, 2-furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 2-pyrazinyl, 2-benzofuranyl, 2-pyridyl-N-oxide, 3-pyridyl-N-oxide, 4-pyridyl-N-oxide, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-pyrrol-2-yl, 4-quinolinyl, 4-pyridyl methyl iodide, dimethylaminophenyl; R 1 is hydrogen or C 1-3 alkyl; s is 1 to 3; X, R 2 and R 3 are as defined hereinabove.
  • R 4 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, pyridyl optionally substituted with C 1-6 alkyl, pyridyl N-oxide optionally substituted with C 1-6 alkyl;
  • X is —O—, —NR 1 —C( ⁇ O)—O—, —NR 1 —C( ⁇ O)—, —NR 1 —C( ⁇ S)—, —NR 1 —C( ⁇ O)—NR 1 —, —NR 1 —C( ⁇ S)—NR 1 —or a direct bond;
  • R 2 is fluoro-substituted C 1-10 alkyl, optionally substituted phenyl or naphthyl, optionally substituted phenylC 1-6 alkyl, a monocyclic, bicyclic or tricyclic saturated carbocycle consisting of from 3 to 10 carbon atoms, a monocyclic, bicyclic or tricyclic partially saturated carbocycle consisting of from 3 to
  • Also preferred compounds are those compounds of formula (I) or (I′) wherein ring A is pyridyl, pyrimidinyl or pyridazinyl, in particular pyrimidinyl or pyridazinyl.
  • ring A is pyridyl, pyrimidinyl or pyridazinyl; in particular pyrimidinyl or pyridazinyl;
  • Still other preferred compounds are those compounds of formula (I) or (I′) wherein ring A is pyridyl, pyrimidinyl or pyridazinyl; in particular pyrimidinyl or pyridazinyl;
  • (b) s is 1 and said R 3 substituent is placed at the para position of the NR 1 linker and is other than C 1-6 alkyloxy or polyhaloC 1-6 alkyloxy;
  • X is other than a direct bond or C 1-6 alkyl
  • X—R 2 is other than hydroxy, C 1-6 alkyl, C 1-6 alkyloxy, trihalomethyl,
  • R 4 is an optionally substituted 5-membered heterocycle with at least 2 nitrogen atoms
  • R 2 is other than hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and X is other than O,
  • R 2 is other than hydrogen.
  • X is other than a direct bond or C 1-6 alkyl
  • R 2 is other than hydrogen, trifluoromethyl or C 1-4 alkyl
  • X—R 2 is other than hydroxy, C 1-6 alkyl, C 1-6 alkyloxy, trihalomethyl,
  • R 4 is an optionally substituted 5-membered heterocycle.
  • R 4 is an optionally substituted 5-membered heterocycle, in particular an optionally substituted imidazolyl or an optionally substituted triazolyl and/or wherein Z is a direct bond.
  • Particular preferred compounds of formula (I) or (I′) are selected from N 2 -(1H-indazol-5-yl)-N 4 -(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine; 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-2-(phenylmethoxy)-benzonitrile; 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.
  • Compounds of formula (I) can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W 1 represents a suitable leaving group, such as for example a halo atom, e.g. chloro, bromo and the like, in the presence of a suitable solvent, such as for example N N-dimethylacetamide, acetonitrile, tetrahydrofuran, water, an alcohol, e.g. methanol, ethanol, isopropanol and the like, and optionally in the presence of a suitable acid, such as for example hydrochloric acid and the like.
  • a suitable solvent such as for example N N-dimethylacetamide, acetonitrile, tetrahydrofuran
  • water an alcohol, e.g. methanol, ethanol, isopropanol and the like
  • a suitable acid such as for example hydrochloric acid and the like.
  • the above reaction may also be performed in the presence of a suitable solvent, such as for example toluene, a suitable catalyst, such as tris (dibenzylidene aceton)dipalladium (0), a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1′-binaphthyl, and a suitable base, such as for example sodium tert.butoxide.
  • a suitable solvent such as for example toluene
  • a suitable catalyst such as tris (dibenzylidene aceton)dipalladium (0)
  • a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1′-binaphthyl
  • a suitable base such as for example sodium tert.butoxide.
  • Compounds of formula (I) can also be prepared by reacting an intermediate of formula (IV) wherein W 2 represents a suitable leaving group, such as for example a halo atom, e.g. chloro and the like, with an intermediate of formula (V) in the presence of a suitable solvent, such as for example toluene, a suitable catalyst, such as tris (dibenzylidene aceton)dipalladium (0), a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1′-binaphthyl, and a suitable base, such as for example sodium tert.butoxide.
  • a suitable solvent such as for example toluene
  • a suitable catalyst such as tris (dibenzylidene aceton)dipalladium (0)
  • a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1′-binaphthyl
  • a suitable base
  • Compounds of formula (I) may also be prepared by reacting an intermediate of formula (VI), wherein W 3 represents a suitable leaving group, such as a halo atom, e.g. chloro and the like, with an intermediate of formula (VII) in the presence of a suitable solvent, such as 1,4-dioxane or an alcohol, e.g. methanol, ethanol, isopropanol and the like, or water, optionally in the presence of a suitable acid, such as hydrochloric acid and the like, or a suitable base, such as for example N,N-diisopropylethanamine.
  • a suitable solvent such as 1,4-dioxane or an alcohol, e.g. methanol, ethanol, isopropanol and the like
  • a suitable acid such as hydrochloric acid and the like
  • a suitable base such as for example N,N-diisopropylethanamine.
  • Compounds of formula (I) wherein Z is C( ⁇ O), said compounds being represented by formula (I-a), may be prepared by reacting an intermediate of formula (VIII), wherein W 4 represents a suitable leaving group, such as a halo atom, e.g. chloro and the like, or an alcoholate, such as methanolate, ethanolate and the like, with an intermediate of formula (IX) in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like.
  • a suitable solvent such as for example an alcohol, e.g. methanol, ethanol and the like.
  • Compounds of formula (I) wherein Z is a direct bond can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (X) in the presence of a suitable catalyst, such as for example palladium tetrakis(triphenylphosphine), a suitable base, such as for example disodium carbonate, and a suitable solvent, such as for example acetonitrile and water.
  • a suitable catalyst such as for example palladium tetrakis(triphenylphosphine
  • a suitable base such as for example disodium carbonate
  • a suitable solvent such as for example acetonitrile and water.
  • Compounds of formula (I) wherein Z is a direct bond and R 4 represents 5-tetrazolyl, said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (XI) with sodium azide in the presence of a suitable salt, such as for example N,N-diethylethanamine hydrochloric acid salt, and a suitable solvent, such as for example 1-methyl-2-pyrrolidinone.
  • a suitable salt such as for example N,N-diethylethanamine hydrochloric acid salt
  • a suitable solvent such as for example 1-methyl-2-pyrrolidinone.
  • Compounds of formula (I) wherein Z is a direct bond and ring A is pyrimidinyl with the NR 1 linker placed in position 2, said compounds being represented by formula (I-d), may be prepared by reacting an intermediate of formula (XX) with an intermediate of formula (XXI) in the presence of a suitable solvent, such as for example N,N-dimethylacetamide and a suitable base, such as for example sodium ethanolate.
  • a suitable solvent such as for example N,N-dimethylacetamide
  • a suitable base such as for example sodium ethanolate.
  • R 4 in a compound of formula (I-d) represents a heterocycle substituted with amino are aminocarbonyl
  • R 4 in an intermediate of formula (XXI) may represent a heterocycle substituted with —N ⁇ CH—N(CU 3 ) 2 or —C( ⁇ O)—N ⁇ CH—N(CH 3 ) 2 .
  • reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.
  • the compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
  • the compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form.
  • Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide;
  • appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g.
  • 3-chlorobenzenecarbo-peroxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • Compounds of formula (I) wherein R 3 is halo, or wherein R 2 is substituted with halo can be converted into a compound of formula (I) wherein R 3 is cyano, or wherein R 2 is substituted with cyano, by reaction with a suitable cyano-introducing agent, such as sodium cyanide or CuCN, optionally in the presence of a suitable catalyst, such as for example tetrakis(triphenylphosphine)palladium and a suitable solvent, such as N,N-dimethylacetamide or N,N-dimethylformamide.
  • a suitable cyano-introducing agent such as sodium cyanide or CuCN
  • a suitable catalyst such as for example tetrakis(triphenylphosphine)palladium
  • a suitable solvent such as N,N-dimethylacetamide or N,N-dimethylformamide.
  • a compound of formula (I) wherein R 3 is cyano, or wherein R 2 is substituted with cyano can further be converted into a compound of formula (I) wherein R 3 is aminocarbonyl, or wherein R 1 is substituted with aminocarbonyl, by reaction with HCOOH, in the presence of a suitable acid, such as hydrochloric acid.
  • a compound of formula (I) wherein R 3 is cyano, or wherein R 2 is substituted with cyano can also further be converted into a compound of formula (I) wherein R 3 is tetrazolyl, or wherein R 2 is substituted with tetrazolyl, by reaction with sodium azide in the presence of ammonium chloride and N,N-dimethylacetoacetamide.
  • Compounds of formula (I) wherein —X—R 2 is —O—CH 2 — (optionally substituted)phenyl may be converted into a compound of formula (I) wherein —X—R 2 represents OH, by reaction with a suitable reducing agent, such as H 2 , in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like, or N,N-dimethylacetamide.
  • a suitable reducing agent such as H 2
  • a suitable catalyst such as for example palladium on charcoal
  • a suitable solvent such as for example an alcohol, e.g. methanol, ethanol and the like, or N,N-dimethylacetamide.
  • —O—X 1 represents those linkers falling under the definition of X which are attached to the phenyl ring via a O atom (in said definition X 1 represents that part of the linker wherein the O atom is not included), in the presence of a suitable base, such as for example dipotassium carbonate, and a suitable solvent, such as for example N,N-dimethylacetamide.
  • a suitable base such as for example dipotassium carbonate
  • a suitable solvent such as for example N,N-dimethylacetamide.
  • Compounds of formula (I) wherein R 3 is nitro, or wherein R 2 is substituted with nitro may be converted into a compound of formula (I) wherein R 3 is amino or wherein R 2 is substituted with amino, by reaction with a suitable reducing agent, such as for example H 2 , in the presence of a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like.
  • a suitable reducing agent such as for example H 2
  • a suitable catalyst poison such as for example a thiophene solution
  • a suitable solvent such as for example an alcohol, e.g. methanol, ethanol and the like.
  • Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom.
  • Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures.
  • diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods.
  • Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g.
  • Intermediates of formula (II) wherein R 1 is hydrogen, said intermediates being represented by formula (II-a), can be prepared by reducing an intermediate of formula (XII) in the presence of a suitable reducing agent, such as for example H 2 , a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol, ethanol and the like.
  • a suitable reducing agent such as for example H 2
  • a suitable catalyst such as for example palladium on charcoal
  • a suitable catalyst poison such as for example a thiophene solution
  • a suitable solvent such as for example tetrahydrofuran or an alcohol, e.g. methanol, ethanol and the like.
  • Intermediates of formula (III) can be prepared by reacting an intermediate of formula (XIII) wherein W 1 is as defined hereinabove, with an intermediate of formula (XIV) in the presence of a suitable solvent, such as for example acetonitrile or dioxane, and optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine.
  • a suitable solvent such as for example acetonitrile or dioxane
  • a suitable base such as for example N,N-diisopropylethanamine.
  • Intermediates of formula (IV) can be prepared by reacting an intermediate of formula (XV) wherein W 2 is as defined hereinabove, with an intermediate of formula (XVI) wherein W 2 is as defined hereinabove.
  • Intermediates of formula (XVI) can be prepared by reacting an intermediate of formula (XVII) with a leaving group introducing agent of formula (XVIII) wherein W 2 represents the leaving group and R represents the remaining of the leaving group introducing agent, such as for example POCl 3 .
  • Intermediates of formula (VI) can be prepared by reacting an intermediate of formula (XIX) wherein W 3 is as defined hereinabove, with an intermediate of formula (III) in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol, isopropanol and the like, and a suitable acid, such as for example hydrochloric acid.
  • a suitable solvent such as for example an alcohol, e.g. methanol, ethanol, isopropanol and the like
  • a suitable acid such as for example hydrochloric acid.
  • Intermediates of formula (VIII) wherein ring A is pyrimidinyl with the NR 1 linker in position 2 and W 4 represents an alcoholate, i.e. C 1-6 alkylO—, said intermediates being represented by formula (VIII-a), may be prepared by reacting an intermediate of formula (XX) with an intermediate of formula (XXII) in the presence of a suitable solvent, such as for example N,N-dimethylacetamide.
  • Intermediates of formula (XX) can be prepared by reacting an intermediate of formula (V) with cyanamide in the presence of a suitable solvent, such as for example diglyme.
  • the compounds of formula (I) or (I′) inhibit Glycogen synthase kinase 3 (GSK3), in particular glycogen synthase kinase 3 beta (GSK3 ⁇ ). They are selective Glycogen synthase kinase 3 inhibitors. Specific inhibitory compounds are superior therapeutic agents since they are characterized by a greater efficacy and lower toxicity by virtue of their specificity.
  • GSK3 tau protein kinase I
  • FA Factor A
  • GSK3 tau protein kinase I
  • ACLK ATP-citrate lysase kinase
  • Glycogen synthase kinase 3 (GSK3), which exists in two isoforms, i.e. GSK3 ⁇ and GSK3 ⁇ , is a proline-directed serine/threonine kinase originally identified as an enzyme that phosphorylates glycogen synthase.
  • GSK3 phosphorylates numerous proteins in vitro such as glycogen synthase, phosphatase inhibitor I-2, the type-II subunit of cAMP-dependent protein kinase, the G-subunit of phosphatase-1, ATP-citrate lyase, acetyl coenzyme A carboxylase, myelin basic protein, a microtubule-associated protein, a neurofilament protein, an N-CAM cell adhesion molecule, nerve growth factor receptor, c-Jun transcription factor, JunD transcription factor, c-Myb transcription factor, c-Myc transcription factor, L-Myc transcription factor, adenomatous polyposis coli tumor supressor protein, tau protein and ⁇ -catenin.
  • proteins in vitro such as glycogen synthase, phosphatase inhibitor I-2, the type-II subunit of cAMP-dependent protein kinase, the G-subunit of phosphatase-1, ATP-cit
  • GSK3 inhibitors may therefore be useful in the prevention or treatment of diseases mediated through GSK3 activity such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, cancer, dermatological disorders such
  • the compounds of the present invention are useful in the prevention or treatment of Alzheimer's disease, diabetes, especially type 2 diabetes (non insulin dependent diabetes).
  • the major neuropathological landmarks in Alzheimer's disease are neuronal loss, the deposition of amyloid fibers and paired helical filaments (PHF) or neurofibrillary tangles (NFT). Tangle formation appears to be the consequence of accumulation of aberrantly phosphorylated tau protein. This aberrant phosphorylation destabilizes neuronal cytoskeleton, which leads to reduced axonal transport, deficient functioning and ultimately neuronal death. The density of neurofibrillary tangles has been shown to parallel duration and severity of Alzheimer's disease. Reduction of the degree of tau phosphorylation can provide for neuroprotection and can prevent or treat Alzheimer's disease or can slow the progression of the disease. As mentioned hereinabove, GSK3 phosphorylates tau protein. Thus compounds having an inhibitory activity for GSK3 may be useful for the prevention or the treatment of Alzheimer's disease.
  • the rate-limiting step in the glycogen synthesis is catalyzed by the enzym glycogen synthase. It is believed that glycogen synthase is inhibited by phosphorylation and that insulin stimulates glycogen synthase by causing a net decrease in the phosphorylation of this enzym.
  • insulin in order to activate glycogen synthase, insulin must either activate phosphatases or inhibit kinases, or both.
  • glycogen synthase is a substrate for glycogen synthase kinase 3 and that insulin inactivates GSK3 thereby promoting the dephosphorylation of glycogen synthase.
  • GSK3 may also play a role in insulin resistance. It is believed that GSK3 dependent Insulin Receptor Substrate-1 phosphorylation contributes to insulin resistance.
  • GSK3 inhibition may result in the increased deposition of glycogen and a concomitant reduction of blood glucose, thus mimicing the hypoglycemic effect of insulin.
  • GSK3 inhibition provides an alternative therapy to manage insulin resistance commonly observed in non insulin dependent diabetes mellitus and obesity.
  • GSK3 inhibitors may thus provide a novel modality for the treatment of type 1 and type 2 diabetes.
  • GSK3 inhibitors in particular GSK3 ⁇ inhibitors, may also be indicated for use in the prevention or the treatment of pain, in particular neuropathic pain.
  • GSK in particular GSK3 ⁇ , has been shown to be involved in the initiation of the apoptotic cascade and trophic factor withdrawal stimulates the GSK3 ⁇ apoptosis pathway.
  • GSK3 ⁇ inhibitors might reduce signals of and even prevent levels of neuropathic pain.
  • GSK3 inhibitory properties are useful to prevent or treat GSK3 mediated diseases, in particular GSK3 ⁇ mediated diseases, such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencepha
  • the present compounds are also useful as male contraceptives.
  • the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from disease mediated through GSK3, in particular GSK3 ⁇ , or they may be useful to prevent warm-blooded animals to suffer from disease mediated through GSK3, in particular GSK3 ⁇ . More in particular, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder.
  • the compounds of formula (I) or any subgroup thereof, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms may be used as a medicine.
  • the present compounds can be used for the manufacture of a medicament for treating or preventing diseases mediated through GSK3, in particular GSK3 ⁇ . More in particular, the present compounds can be used for the manufacture of a medicament for treating or preventing Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder.
  • a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from diseases mediated through GSK3, in particular GSK3 ⁇ , more in particular a method of treating or preventing Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder comprises the administration, preferably oral administration, of an effective amount of a compound of formula (I) or (I′), a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.
  • the present invention also provides compositions for preventing or treating diseases mediated through GSK3, in particular GSK3 ⁇ , comprising a therapeutically effective amount of a compound of formula (I) or (I′) and a pharmaceutically acceptable carrier or diluent.
  • compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • the compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
  • the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the present compounds are orally active compounds, and are preferably orally administered.
  • the exact dosage, the therapeutically effective amount and frequency of administration depends on the particular compound of formula (I) or (I′) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat Alzheimer's disease, such as galantamine, donepezil, rivastigmine or tacrine.
  • the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating Alzheimer's disease. Said combination may be used as a medicine.
  • the present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating Alzheimer's disease, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of Alzheimer's disease.
  • the different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
  • the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat type 2 diabetes, such as glibenclamide, chlorpropamide, gliclazide, glipizide, gliquidon, tolbutamide, metformin, acarbose, miglitol, nateglinide, repaglinide, acetohexamide, glimepiride, glyburide, tolazamide, troglitazone, rosiglitazone, pioglitazone, isaglitazone.
  • other conventional drugs used to combat type 2 diabetes such as glibenclamide, chlorpropamide, gliclazide, glipizide, gliquidon, tolbutamide, metformin, acarbose, miglitol, nateglinide, repaglinide, acetohexamide, glimepiride, glyburide, tolazamide, troglitazone, rosi
  • the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating type 2 diabetes. Said combination may be used as a medicine.
  • the present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating type 2 diabetes, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of type 2 diabetes.
  • the different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
  • the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat cancer such as platinum coordination compounds for example cisplatin or carboplatin; taxane compounds for example paclitaxel or docetaxel; camptothecin compounds for example irinotecan or topotecan; anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine; anti-tumour nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine; nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine; anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 antibodies for example trastzumab; and anti-tumour podophyllotoxin derivatives for example etop
  • the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating cancer. Said combination may be used as a medicine.
  • the present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating cancer, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of cancer.
  • the different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
  • the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat bipolar disorder such as atypical antipsychotics, anti-epileptica, benzodiazepines, lithium salts, for example olanzapine, risperidone, carbamazepine, valproate, topiramate.
  • other conventional drugs used to combat bipolar disorder such as atypical antipsychotics, anti-epileptica, benzodiazepines, lithium salts, for example olanzapine, risperidone, carbamazepine, valproate, topiramate.
  • the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating bipolar disorder. Said combination may be used as a medicine.
  • the present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating bipolar disorder, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of bipolar disorder.
  • the different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
  • the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat inflammatory diseases such as steroids, cyclooxygenase-2 inhibitors, non-steroidal-anti-inflammatory drugs, TNF- ⁇ antibodies, such as for example acetyl salicylic acid, bufexamac, diclofenac potassium, sulindac, diclofenac sodium, ketorolac trometamol, tolmetine, ibuprofen, naproxen, naproxen sodium, tiaprofen acid, flurbiprofen, mefenamic acid, nifluminic acid, meclofenamate, indomethacin, proglumetacine, ketoprofen, nabumetone, paracetamol, piroxicam, tenoxicam, nimesulide, fenylbutazon, tramadol, beclomethasone dipropionate, betamet
  • the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating inflammatory diseases. Said combination may be used as a medicine.
  • the present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating inflammatory diseases, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of inflammatory disorders.
  • the different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
  • DIPE diisopropyl ether
  • DMA diisopropyl ether
  • DMF N,N-dimethylformamide
  • intermediate 3 (0.00477 mol) in DMA (30 ml) was stirred for 1 hour at room temperature and overnight at 100° C. This mixture was again stirred at 100° C. for 24 hours and then cooled to room temperature. The residue was poured out in a saturated NaCl-solution (300 ml), filtered and washed with H 2 O. The precipitate was dissolved in 2-propanone and this solution was concentrated in vacuum. The obtained solid was crystallized from EtOH, filtered and dried at 40° C. under vacuum, yielding 0.64 g (35.8%) of intermediate 6.
  • Tables 1 to 4 list the compounds of formula (I) which were prepared according to one above examples.
  • the pharmacological activity of the present compounds was examined using the following test.
  • GSK3beta assays were performed at 25° C. in a 100 ⁇ l reaction volume of 25 mM Tris (pH 7.4) containing 10 mM MgCl 2 , 1 mM DTT, 0.1 mg/ml BSA, 5% glycerol and containing 19 nM GSK3 ⁇ , 5 ⁇ M biotinylated phosphorylated CREB peptide, 1 ⁇ M ATP, 2 nM ATP-P 33 and a suitable amount of a test compound of formula (I) or (I′). After one hour, the reaction was terminated by adding 70 ⁇ l of Stop mix (1 mM ATP, 18 mg/ml streptavidin coated PVT SPA bead pH 11.0).
  • the beads to which the phosphorylated CREB peptide is attached were allowed to settle for 30 minutes and the radioactivity of the beads was counted in a microtiterplate scintillation counter and compared with the results obtained in a control experiment (without the presence of a test compound) in order to determine the percentage of GSK3 ⁇ , inhibition.
  • the IC 50 value i.e. the concentration (M) of the test compound at which 50% of GSK3, is inhibited, was calculated from the dose response curve obtained by performing the above-described GSK3 ⁇ assay in the presence of different amounts of the test compound.
  • Table 5 lists pIC 50 values (-log IC 50 (M)) obtained in the above-described test for the present compounds.

Abstract

This invention concerns a compound of formula
Figure US07514445-20090407-C00001
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A is a 6-membered heterocycle; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyloxyC1-6alkylcarbonyl; X is a direct bond or a linker atom or group; Z is a direct bond or a linker atom or group; R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, a carbocycle or a heterocycle, each of said groups may optionally be substituted; R3 is hydrogen; hydroxy; halo; optionally substituted C1-6alkyl or C2-6alkenyl or C2-6alkynyl; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R21; R21—C1-6alkyl; R21—O—; R21—S—; R21—C(═O)—; R21—S(═O)p—; R7—S(═O)p—; R7—S(═O)p—NH—; R21—S(═O)p—NH—; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2; R7—C(═O)—NH—; R21—C(═O)—NH—; —C(═NH)R7—C(═NH)R21; R4 is an optionally substituted heterocycle provided that —X—R2 and/or R3 is other than hydrogen; their use, pharmaceutical compositions comprising them and processes for their preparation.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of Application No. PCT/EP02/12077, filed Oct. 29, 2002, which application claims priority from EP 01204196.8 filed Nov. 1, 2001.
The present invention concerns a novel group of heterocyclic derivatives, their use as a medicine, their use for the manufacture of a medicament for the treatment of diseases mediated through glycogen synthase kinase 3; processes for their preparation and pharmaceutical compositions comprising them.
SUMMARY OF THE INVENTION
WO 01/72745 describes 2-substituted 4-heteroaryl-pyrimidines useful in the treatment of proliferative disorders.
WO 98/41512 relates to substituted 2-anilinopyrimidines useful as protein kinase inhibitors.
WO 95/09851 describes pyrimidineamine derivatives useful in the treatment of tumour diseases.
WO 01/12621 describes inhibitors of c-JUN-N-terminal kinases and other protein kinases.
WO 01/60816 describes pyrimidine derivatives useful as kinase inhibitors.
WO 97/19065 discloses substituted 2-anilinopyrimidines useful as p56lck, p59fyn, ZAP-70 and protein kinase C inhibitors.
WO 91/18887 discloses diaminopyrimidine compounds as inhibitors of gastric acid secretion.
WO 99/50250 concerns HIV inhibiting aminopyrimidine derivatives.
U.S. Pat. No. 5,516,775 concerns the use of 2-anilinopyrimidines as protein kinase C inhibitors.
WO 95/09853 describes N-phenyl-2-pyrimidineamine derivatives for the treatment of tumor diseases.
WO 98/18782 concerns 2-pyrimidineamine derivatives as selective protein tyrosine kinase inhibitors.
EP 0,337,943 discloses N-phenyl-N-pyrimidin-2-yl derivatives having herbicidal plant growth regulating activity.
EP 0,164,204 concerns 2-aminopyrimidines which augment the immune respons.
EP 0,233,461 relates to 4,5,6-substituted 2-pyrimidineamines having anti-asthmatic activity.
WO 00/62778 describes cyclic protein tyrosine kinase inhibitors.
U.S. Pat. No. 5,521,184 describes pyrimidine derivatives for the treatment of tumoral diseases.
The present invention relates to compounds which are distinguishable from the prior art in structure, pharmacological activity, potency or selectivity.
DETAILED DESCRIPTION OF THE INVENTION
The present invention concerns a compound of formula (I)
Figure US07514445-20090407-C00002
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl;
  • X is —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C(═S)—; —O—C(═O)—; —C(═O)—O—; —O—C(═O)—C1-6alkyl-; —C(═O)—O—C1-6alkyl-; —O—C1-6alkyl-C(═O)—; —C(═O)—C1-6alkyl-O—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —O—C(═O)—C(═O)—; —C(═O)—NR1—, —NR1—C(═O)—; —C(═S)—NR1—, —NR1—C(═S)—; —NR1—C(═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—; —C1-6alkyl-C(═O)—NR1—; —O—C1-6alkyl-C(═O)—NR1—; —C1-6alkyl-O—C(═O)—NR1—; —C1-6alkyl-; —O—C1-6alkyl-; —C1-6alkyl-O—; —NR1—C1-6alkyl-; —C1-6alkyl-NR1—; —NR1—C1-6alkyl-NR1—; —NR1—C1-6alkyl-C3-7cycloalkyl-; —C2-6alkenyl-; —C2-6alkynyl-; —O—C2-6alkenyl-; —C2-6alkenyl-O—; —NR1—C2-6alkenyl-; —C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-C3-7cycloalkyl-; —O—C2-6alkynyl-; —C2-6alkynyl-O—; —NR1—C2-6alkynyl-; —C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-C3-7cycloalkyl-; —O—C1-6alkyl-O—; —O—C2-6alkenyl-O—; —O—C2-6alkynyl-O—; —CHOH—; —S—; —S(═O)—; —S(═O)2—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —S—C1-6alkyl-; —C1-6alkyl-S—; —S—C2-6alkenyl-; —C2-6alkenyl-S—; —S—C2-6alkynyl-; —C2-6alkynyl-S—; —O—C1-6alkyl-S(═O)2— or a direct bond;
  • Z is a direct bond, C1-6alkanediyl, C2-6alkenediyl, C2-6alkynediyl; —O—; —O—C1-6alkyl-; —S—; —C(═O)—; —C(═O)—O—; —O—C(═O)—; —C(═S)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C1-6alkyl-; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1C(═O)—O—; —NR1—C(═S)—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —NR1—(C═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—;
  • R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C3-7cycloalkyl; R5R6N—C1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)—O—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R3 is hydrogen; hydroxy; halo; C1-6alkyl; C1-6alkyl substituted with cyano, hydroxy or —C(═O)R7; C2-6alkenyl; C2-6alkenyl substituted with one or more halogen atoms or cyano; C2-6alkynyl; C2-6alkynyl substituted with one or more halogen atoms or cyano; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R21; R21—C1-6alkyl; R21—O—; R21—S—; R21—C(═O)—; R21—S(═O)p—; R7—S(═O)p—; R7—S(═O)p—NH—; R21—S(═O)p—NH—; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2; R7—C(═O)—NH—; R21—C(═O)—NH—; —C(═NH)R7; —C(═NH)R7;
  • R4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y1—R8, —Y1—NR9R10, or
  • R5 and R6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14, or each of said heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
  • R7 is C1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino or polyhaloC1-6alkyl;
  • R8 is C1-6alkyl; C2-6alkenyl; C2-6alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R9, R10 and R11 each independently are hydrogen or R8, or
  • any two of R9, R10 and R11 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R12, R13 and R14 each independently are hydrogen; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R15R16N—S(═O)—; R15R16N—S(═O)2—; R17R18N—Y1—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—; oxo, or
  • any two of R12, R13 and R14 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo—or heterocycle or an aromatic 4 to 8 membered monocyclic carbo—or heterocycle together with the atoms to which they are attached, or
  • any two of R12, R13 and R14 may together be —O—(CH2)r—O— thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo—or heterocycle together with the atoms to which they are attached;
  • R15 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R15 may optionally be substituted with one or more substituents selected from R12, R13 and R14; or each of said carbocycles or heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
  • R16, R17, R18 and R19 each independently are hydrogen or R15, or
  • R17 and R18, or R15 and R19 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14; or
  • R17 and R18 together with R16 may be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
  • R21 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R21 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • Y1a is —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y1 or Y2 each independently are a direct bond, —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl;
  • n is 1 or 2;
  • m is 1 or 2;
  • p is 1 or 2;
  • r is 1 to 5;
  • s is 1 to 3;
  • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy;
  • provided that —X—R2 and/or R3 is other than hydrogen; and
  • provided that when
Figure US07514445-20090407-C00003
then
  • -Z is other than a direct bond or NH when R1 is hydrogen or methyl, s is 2, R3 is methoxy, and —X—R2 is methoxy;
  • -Z—R4 is other than 3-pyridyl, 4-pyridyl or 4-pyridyl N-oxide when R1 is hydrogen or methyl, s is 1, R3 is 3-chloro or 4-methoxy, and —X—R2 is hydrogen;
  • -Z—R4 is other than
Figure US07514445-20090407-C00004
when R1 is hydrogen;
  • —R3 and —X—R2 are other than hydrogen when R1 is hydrogen and -Z—R4 is 3-pyridyl or substituted 4-pyridyl;
  • and provided that when
Figure US07514445-20090407-C00005
then
  • —R4 is other than pyridyl optionally substituted with methyl, pyridyl N-oxide, 1-methyl-pyridinium, thienyl optionally substituted with one or two methyl groups, furanyl optionally substituted with one or two methyl groups, benzofuranyl, quinolinyl, indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl; and provided that the following compounds
Figure US07514445-20090407-C00006
are not included.
The present invention also relates to the use of a compound for the manufacture of a medicament for the prevention or the treatment of diseases mediated through GSK3, said compound being a compound of formula (I′)
Figure US07514445-20090407-C00007
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl;
  • X is —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C(═S)—; —O—C(═O)—; —C(═O)—O—; —O—C(═O)—C1-6alkyl-; —C(═O)—O—C1-6alkyl-; —O—C1-6alkyl-C(═O)—; —C(═O)—C1-6alkyl-O—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —O—C(═O)—C(═O)—; —C(═O)—NR1—, —NR1—C(═O)—; —C(═S)—NR1—, —NR1—C(═S)—; —NR1—C(═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—; —C1-6alkyl-C(═O)—NR1—; —O—C1-6alkyl-C(═O)—NR1—; —C1-6alkyl-O—C(═O)—NR1—; —C1-6alkyl-; —O—C1-6alkyl-; —C1-6alkyl-O—; —NR1—C1-6alkyl-; —C1-6alkyl-NR1—; —NR1—C1-6alkyl-NR1—; —NR1—C1-6alkyl-C3-7cycloalkyl-; —C2-6alkenyl-; —C2-6alkynyl-; —O—C2-6alkenyl-; —C2-6alkenyl-O—; —NR1—C2-6alkenyl-; —C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-C3-7cycloalkyl-; —O—C2-6alkynyl-; —C2-6alkynyl-O—; —NR1—C2-6alkynyl-; —C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-C3-7cycloalkyl-; —O—C1-6alkyl-O—; —O—C2-6alkenyl-O—; —O—C2-6alkynyl-O—; —CHOH—; —S—; —S(═O)—; —S(═O)2—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —S—C1-6alkyl-; —C1-6alkyl-S—; —S—C2-6alkenyl-; —C2-6alkenyl-S—; —S—C2-6alkynyl-; —C2-6alkynyl-S—; —O—C1-6alkyl-S(═O)2— or a direct bond;
  • Z is a direct bond, C1-6alkanediyl, C2-6alkenediyl, C2-6alkynediyl; —O—; —O—C1-6alkyl-; —S—; —C(═O)—; —C(═O)—O—; —O—C(═O)—; —C(═S)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C1-6alkyl-; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1C (═O)—O—; —NR1—C(═S)—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —NR1—(C═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—;
  • R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C3-7cycloalkyl; R5R6N—C1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O), —NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR6—Y1—; R5—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R3 is hydrogen; hydroxy; halo; C1-6alkyl; C1-6alkyl substituted with cyano, hydroxy or —C(═O)R7; C2-6alkenyl; C2-6alkenyl substituted with one or more halogen atoms or cyano; C2-6alkynyl; C2-6alkynyl substituted with one or more halogen atoms or cyano; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R21; R21—C1-6alkyl; R2—O—; R2—S—; R21—C(═O)—; R21—S(═O)n—; R7—S(═O)p—; R7—S(═O)p—NH—; R2—S(═O)p—NH—; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2; R7—C(═O)—NH—; R21—C(═O)—NH—; —C(═NH)R7; —C(═NH)R21;
  • R4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n, —NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n, —NH—; R5—O—S(═O), —NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y1—R8, —Y, —NR9R10, or
  • R5 and R6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14, or each of said heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
  • R7 is C1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino or polyhaloC1-6alkyl;
  • R8 is C1-6alkyl; C2-6alkenyl; C2-6alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R9, R10 and R11 each independently are hydrogen or R8, or
  • any two of R9, R10 and R11 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R12, R13 and R14 each independently are hydrogen; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R15R16N—S(═O)—; R15R16N—S(═O)2—; R17R18N—Y1—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—; oxo, or
  • any two of R12, R13 and R14 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo—or heterocycle or an aromatic 4 to 8 membered monocyclic carbo—or heterocycle together with the atoms to which they are attached, or any two of R12, R13 and R14 may together be —O—(CH2)r—O— thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo—or heterocycle together with the atoms to which they are attached;
  • R15 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R15 may optionally be substituted with one or more substituents selected from R12, R13 and R14; or each of said carbocycles or heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
  • R16, R17, R18 and R19 each independently are hydrogen or R15, or
  • R17 and R18, or R15 and R19 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14; or
  • R17 and R18 together with R16 may be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
  • R21 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R21 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • Y1a is —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y1 or Y2 each independently are a direct bond, —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl;
  • n is 1 or 2;
  • m is 1 or 2;
  • p is 1 or 2;
  • r is 1 to 5;
  • s is 1 to 3;
  • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy; provided that —X—R2 and/or R3 is other than hydrogen.
As used herein C1-3alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl; C1-4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the groups defined for C1-3alkyl and butyl; C1-6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C1-4alkyl and pentyl, hexyl, 2-methylbutyl and the like; C1-10alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for C1-6alkyl and heptyl, octyl, nonyl, decyl and the like; C1-6alkanediyl as a group or part of a group defines bivalent straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as methylene, 1,2-ethanediyl or 1,2-ethylidene, 1,3-propanediyl or 1,3-propylidene, 1,4-butanediyl or 1,4-butylidene and the like; C2-6alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like; C2-10alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 10 carbon atoms containing a double bond such as the groups defined for C2-6alkenyl and heptenyl, octenyl, nonenyl, decenyl and the like; C2-6alkenediyl defines bivalent straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing one or more double bonds such as ethenediyl, propenediyl, butenediyl, pentenediyl, hexenediyl and the like; C2-6alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a triple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like; C2-10alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 10 carbon atoms containing a triple bond such as the groups defined for C2-6alkynyl and heptynyl, octynyl, nonynyl, decynyl and the like; C2-6alkynediyl defines bivalent straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a triple bond such as ethynediyl, propynediyl, butynediyl, pentynediyl, hexynediyl and the like; C3-7cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; a monocyclic, bicyclic or tricyclic saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and comprising at least, one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic carbocycle represents an aromatic ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms; the term aromatic is well known to a person skilled in the art and designates cyclically conjugated systems of 4n′30 2 electrons, that is with 6, 10, 14 etc. π-electrons (rule of Hückel; n′ being 1, 2,3 etc.); a monocyclic, bicyclic or tricyclic saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, and at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic heterocycle represents an aromatic ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S.
Particular examples of monocyclic, bicyclic or tricyclic saturated carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[4,2,0]octanyl, cyclononanyl, cyclodecanyl, decahydronapthalenyl, tetradecahydroanthracenyl.
Particular examples of monocyclic, bicyclic or tricyclic partially saturated carbocycles are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclo-octenyl, bicyclo[4,2,0]octenyl, cyclononenyl, cyclodecenyl, octahydronaphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4,4a,9,9a,10-octahydro-anthracenyl.
Particular examples of monocyclic, bicyclic or tricyclic aromatic carbocycles are phenyl, naphthalenyl, anthracenyl.
Particular examples of monocyclic, bicyclic or tricyclic saturated heterocycles are tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, decahydroquinolinyl, octahydroindolyl.
Particular examples of monocyclic, bicyclic or tricyclic partially saturated heterocycles are pyrrolinyl, imidazolinyl, pyrazolinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolinyl and the like.
Particular examples of monocyclic, bicyclic or tricyclic aromatic heterocycles are azetyl, oxetylidenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl, naphthiridinyl, pteridinyl, benzopyranyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl, isothiazolopyrazinyl, thiazolopyrazinyl, isoxazolopyrazinyl, oxazolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, pyrrolopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, isothiazolopyrimidinyl, thiazolopyrimidinyl, isoxazolopyrimidinyl, oxazolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, pyrrolopyridazinyl, thienopyridazinyl, furopyridazinyl, isothiazolopyridazinyl, thiazolopyridazinyl, isoxazolopyridazinyl, oxazolopyridazinyl, pyrazolopyridazinyl, imidazopyridazinyl, oxadiazolopyridyl, thiadiazolopyridyl, triazolopyridyl, oxadiazolopyrazinyl, thiadiazolopyrazinyl, triazolopyrazinyl, oxadiazolopyrimidinyl, thiadiazolopyrimidinyl, triazolopyrimidinyl, oxadiazolopyridazinyl, thiadiazolopyridazinyl, triazolopyridazinyl, imidazooxazolyl, imidazothiazolyl, imidazoimidazolyl, isoxazolotriazinyl, isothiazolo-triazinyl, pyrazolotriazinyl, oxazolotriazinyl, thiazolotriazinyl, imidazotriazinyl, oxadiazolotriazinyl, thiadiazolotriazinyl, triazolotriazinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl.
Particular examples of 5-membered aromatic heterocycles are pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl.
As used herein before, the term (═O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.
The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhalomethyl as a group or part of a group is defined as mono- or polyhalosubstituted methyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl; polyhaloC1-6alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C1-6alkyl, for example, the groups defined in halomethyl, 1,1-difluoro-ethyl and the like. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhalomethyl or polyhaloC1-6alkyl, they may be the same or different.
The term heterocycle as in the definition of for instance R4, R5, R6, R8 or R15 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl also includes 2H-pyrrolyl.
The hereinabove-mentioned carbocycles may be attached to the remainder of the molecule of formula (I) or (I′) through any ring carbon as appropriate, if not otherwise specified. Thus, for example, when the partially saturated bicyclic carbocycle is 1,2,3,4-tetrahydronaphthalenyl, it may be 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl and the like.
The hereinabove-mentioned heterocycles may be attached to the remainder of the molecule of formula (I) or (I′) through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when the aromatic monocyclic heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like.
When any variable (eg. R5, R6 etc.) occurs more than one time in any constituent, each definition is independent.
Lines drawn into ring systems from substituents indicate that the bond may be attached to any of the suitable ring atoms.
For therapeutic use, salts of the compounds of formula (I) or (I′) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) or (I′) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.
The compounds of formula (I) or (I′) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.
The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) or (I′) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
The term “quaternary amine” as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) or (I′) are able to form by reaction between a basic nitrogen of a compound of formula (I) or (I′) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.
It will be appreciated that some of the compounds of formula (I) or (I′) and their N-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.
The term “stereochemically isomeric forms” as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I) or (I′), and their N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) or (I′) and their N-oxides, salts, solvates or quaternary amines substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereochemically isomeric forms of the compounds of formula (I) or (I′) are obviously intended to be embraced within the scope of this invention.
The N-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called N-oxide.
Some of the compounds of formula (I) or (I′) may also exist in their tautomeric form (e.g. keto-enol tautomerie). Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
Whenever used hereinafter, the term “compounds of formula (I)” or “compounds of formula (I) or (I′) is meant to also include their N-oxide forms, their salts, their quaternary amines and their stereochemically isomeric forms. Of special interest are those compounds of formula (I) or (I′) which are stereochemically pure.
Particular compounds are those compounds of formula (I) or (I′) as defined hereinabove provided that the molecular mass of the compounds is at most 1000 u, in particular at most 800 u, more in particular at most 700 u (u stands for unified atomic mass unit and equals 1.66×10−27 kg).
Particular compounds are also those compounds of formula (I) or (I′) as defined hereinabove provided that when R3 is hydrogen then X is other than —C(═O)—NR1—or —C(═S)—NR1—; and provided that when X is a direct bond and R2 is hydrogen than R3 is other than R7—C(═O)— with R7 representing amino or mono- or di(C1-6alkyl)amino; and provided that when X is a direct bond and R2 is hydrogen than R21 is other than a heterocycle; and
provided that when R3 is hydrogen then R2 is other than a heterocycle.
Particular interesting compounds are those compounds of formula (I) or (I′) as defined hereinabove, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein ring A is pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl;
  • X is —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C(═S)—; —O—C(═O)—; —C(═O)—O—; —O—C(═O)—C1-6alkyl-; —C(═O)—O—C1-6alkyl-; —O—C1-6alkyl-C(═O)—; —C(═O)—C1-6alkyl-O—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —O—C(═O)—C(═O)—; —C(═O)—NR1—, —NR1—C(═O)—; —C(═S)—NR1—, —NR1—C(═S)—; —NR1—C(═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—; —C1-6alkyl-C(═O)—NR1—; —O—C1-6alkyl-C(═O)—NR1—; —C1-6alkyl-O—C(═O)—NR1—; —C1-6alkyl-; —O—C1-6alkyl-; —C1-6alkyl-O—; —NR1—C1-6alkyl-; —C1-6alkyl-NR1—; —NR1—C1-6alkyl-NR1—; —NR1—C1-6alkyl-C3-7cycloalkyl-; —C2-6alkenyl-; —C2-6alkynyl-; —O—C2-6alkenyl-; —C2-6alkenyl-O—; —NR1—C2-6alkenyl-; —C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-C3-7cycloalkyl-; —O—C2-6alkynyl-; —C2-6alkynyl-O—; —NR1—C2-6alkynyl-; —C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-C3-7cycloalkyl-; —O—C1-6alkyl-O—; —O—C2-6alkenyl-O—; —O—C2-6alkynyl-O—; —CHOH—; —S—; —S(═O)—; —S(═O)2—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —S—C1-6alkyl-; —C1-6alkyl-S—; —S—C2-6alkenyl-; —C2-6alkenyl-S—; —S—C2-6alkynyl-; —C2-6alkynyl-S—; —O—C1-6alkyl-S(═O)2— or a direct bond;
  • Z is a direct bond, C1-6alkanediyl, C2-6alkenediyl, C2-6alkynediyl; —O—; —O—C1-6alkyl-; —S—; —C(═O)—; —C(═O)—O—; —O—C(═O)—; —C(═S)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C1-6alkyl-; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1C (═O)—O—; —NR1—C(═S)—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —NR1—(C═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—;
  • R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C3-7cycloalkyl; R5R6N—C1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O), —NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18 N—Y1a—; R17R8N—Y2—NR6—Y1—; R5—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R3 is hydrogen; hydroxy; halo; C1-6alkyl; C1-6alkyl substituted with cyano, hydroxy or —C(═O)R7; C2-6alkenyl; C2-6alkenyl substituted with one or more halogen atoms or cyano; C2-6alkynyl; C2-6alkynyl substituted with one or more halogen atoms or cyano; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R21; R21—C1-6alkyl; R21—O—; R21—S—; R21—C(═O)—; R21—S(═O)p—; R7—S(═O)p—; R7—S(═O)p—NH—; R21—S(═O)p—NH—; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2; R7—C(═O)—NH—; R21—C(═O)—NH—; —C(═NH)R7; —C(═NH)R21;
  • R4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17 R18 N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y, —R8, —Y1—NR9R10;
  • R7 is C1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino or polyhaloC1-6alkyl;
  • R8 is C1-6alkyl; C2-6alkenyl; C2-6alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R9, R10 and R11 each independently are hydrogen or R8;
  • R12, R13 and R14 each independently are hydrogen; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R5—S(═O)2—; R5R16N—S(═O)—; R15R16N—S(═O)2—; R17R18N—Y1—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—; oxo;
  • R15 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R15 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R16, R17, R18 and R19 each independently are hydrogen or R15;
  • R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
  • R21 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R21 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • Y1a is —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y1 or Y2 each independently are a direct bond, —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl;
  • n is 1 or 2;
  • m is 1 or 2;
  • p is 1 or 2;
  • r is 1 to 5;
  • s is 1 to 3;
  • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy;
  • provided that —X—R2 and/or R3 is other than hydrogen; and
  • provided that when
Figure US07514445-20090407-C00008
then
  • -Z is other than a direct bond or NH when R1 is hydrogen or methyl, s is 2, R3 is methoxy, and —X—R2 is methoxy;
  • -Z—R4 is other than 3-pyridyl, 4-pyridyl or 4-pyridyl N-oxide when R1 is hydrogen or methyl, s is 1, R3 is 3-chloro or 4-methoxy, and —X—R2 is hydrogen;
  • -Z—R4 is other than
Figure US07514445-20090407-C00009
when R1 is hydrogen;
  • —R3 and —X—R2 are other than hydrogen when R1 is hydrogen and -Z—R4 is 3-pyridyl or substituted 4-pyridyl;
  • and provided that when
Figure US07514445-20090407-C00010
then
  • —R4 is other than pyridyl optionally substituted with methyl, pyridyl N-oxide, 1-methyl-pyridinium, thienyl optionally substituted with one or two methyl groups, furanyl optionally substituted with one or two methyl groups, benzofuranyl, quinolinyl, indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl; and provided that the following compounds
Figure US07514445-20090407-C00011
are not included.
Further interesting compounds are those compounds of formula (I) or (I′) as defined hereinabove, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein ring A is pyridyl, pyrimidinyl or pyridazinyl;
  • R1 is hydrogen;
  • X is a direct bond, —O— or —O—C1-6alkyl-;
  • Z is a direct bond, —NR1—, —NR1—C1-6alkyl- or —C(═O)—;
  • R2 is hydrogen or R20;
  • R3 is hydrogen, halo, C1-6alkyl, polyhaloC1-6alkyl or cyano;
  • R4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from R15, R15—O—, R15—C(═O)— or halo;
  • R15 is C1-6alkyl; a monocyclic, bicyclic or tricyclic saturated heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic aromatic carbocycle;
  • R20 is a monocyclic, bicyclic or tricyclic aromatic carbocycle;
  • s is 1 to 3;
  • provided that —X—R2 and/or R3 is other than hydrogen; and
  • provided that when
Figure US07514445-20090407-C00012
then
  • -Z—R4 is other than 3-pyridyl, 4-pyridyl or 4-pyridyl N-oxide when s is 1,
  • R3 is 3-chloro, and —X—R2 is hydrogen;
  • -Z—R4 is other than
Figure US07514445-20090407-C00013
  • —R3 and —X—R2 are other than hydrogen when -Z—R4 is 3-pyridyl or substituted 4-pyridyl;
  • and provided that when
Figure US07514445-20090407-C00014
then
  • —R4 is other than pyridyl optionally substituted with methyl, pyridyl N-oxide, 1-methyl-pyridinium, thienyl optionally substituted with one or two methyl groups, furanyl optionally substituted with one or two methyl groups, benzofuranyl, quinolinyl, indolyl, pyrrolyl optionally substituted with methyl, pyrimidinyl, phenothiazinyl;
  • Also interesting compounds are those compounds of formula (I) or (I′) as defined hereinabove provided that the compound is other than
Figure US07514445-20090407-C00015
wherein
  • X is —O—; R2 is C1-10alkyl, C2-10alkenyl or C2-10alkynyl, said groups representing R2 may optionally be substituted; R3a is C1-6alkyloxy; R3b is hydrogen, halo, optionally substituted C1-10alkyl, optionally substituted C2-10alkenyl, optionally substituted C2-10alkynyl, hydroxy, amino, mono- or di(C1-6alkyl)amino, C1-6alkyl-C(═O)—NH—, C1-6alkyloxy, polyhaloC1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkylthio, aryloxy; R1 is hydrogen or C1-6alkyl and Z-R4 is as defined hereinabove;
Figure US07514445-20090407-C00016
wherein
  • Z is C1-6alkanediyl, C2-6alkenediyl, —C(═O)— or —C(═S)—; ring A is as defined hereinabove; R4 is monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, said groups representing R4 may optionally be substituted; R1 is hydrogen; aryl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl; X is a direct bond or C1-6alkyl; R2, R3 and s are as defined hereinabove;
Figure US07514445-20090407-C00017
wherein
  • X is a direct bond, —O—, —S—, —C(═O)—NH—, —C(═O)—O—; R2 is hydrogen, CF3, C1-4alkyl;
  • R3 is hydrogen, hydroxy, halo, CF3, C1-4alkyl, C1-4alkyloxy, C1-4alkylthio, cyano, amino, aminocarbonyl, carboxyl, C1-4alkylcarbonyl; R1 is hydrogen or C1-4alkyl; R4, R3 and s are as defined hereinabove;
Figure US07514445-20090407-C00018
wherein
  • R4-Z represents indolyl-C1-10alkyl or Z is a direct bond, —C1-6alkyl-, —NR1—, —NH—NH—, —N═N—, —O—, —(C═O)—, —CHOH—, —S—, —S(═O)—, —S(═O)2—, —O—C1-4alkyl-, —NR; —C1-4alkyl-, —S—C1-4alkyl- and R4 is pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, said groups representing R4 may optionally be substituted; R1 is hydrogen, aryl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl; X—R2 is hydrogen, hydroxy, C1-6alkyl, C1-6alkyloxy, trihalomethyl, trihalomethyloxy, cyanoC1-6alkyl; R3a is halo, C1-6alkyl, cyano, nitro, trihalomethyl, trihalomethyloxy or C1-6alkyl substituted with cyano or aminocarbonyl; R3b is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; s is 0, 1 or 2;
Figure US07514445-20090407-C00019
wherein
  • R4 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 4-methyl-3-pyridyl, 2-furyl, 5-methyl-2-furyl, 2,5-dimethyl-3-furyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, 4-pyrazinyl, 2-benzofuryl, N-oxido-2-pyridyl, N-oxido-3-pyridyl, N-oxido-4-pyridyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-pyrrol-2-yl, 4-quinolinyl, 1-methyl-pyridinium-4-yliodide; R1 is hydrogen or C1-3alkyl; X—R2, R3 and s are as defined hereinabove;
Figure US07514445-20090407-C00020
wherein
  • R4 is N-methylpiperazinyl, piperidinyl, imidazolyl, triazolyl, benzimidazolyl, 4-phenyl-piperazin-1-yl wherein phenyl may optionally be substituted with C1-3alkyl or C1-3alkyloxy or halo or trifluoromethyl, 1H-imidazol-1-ylC1-3alkyl, 1H-imidazol-1-ylC1-3alkyloxy, 1H-imidazol-1-ylC1-3alkylthio, morpholinylC1-3alkyl, morpholinylC1-3alkyloxy, morpholinylC1-3alkylthio; X is a direct bond; R2 is hydrogen, C1-3alkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 4-methyl-3-pyridyl, 2-furyl, 5-methyl-2-furyl, 2,5-dimethyl-3-furyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, 4-pyrazinyl, 2-benzofuryl, N-oxido-2-pyridyl, N-oxido-3-pyridyl, N-oxido-4-pyridyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-pyrrol-2-yl, 4-quinolinyl, 1-methyl-pyridinium-4-yliodide; R3 is hydrogen, C1-3alkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 4-methyl-3-pyridyl, 2-furyl, 5-methyl-2-furyl, 2,5-dimethyl-3-furyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, 4-pyrazinyl, 2-benzofuryl, N-oxido-2-pyridyl, N-oxido-3-pyridyl, N-oxido-4-pyridyl, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-pyrrol-2-yl, 4-quinolinyl, 1-methyl-pyridinium-4-yliodide; s is as defined hereinbove;
Figure US07514445-20090407-C00021
wherein
  • R4 is pyridyl substituted with an optionally substituted monocyclic, bicyclic or tricyclic saturated heterocycle consisting of from 3 to 7 atoms, and X, R2, R3 and s are as defined hereinabove;
Figure US07514445-20090407-C00022
wherein R4 is 4-pyridyl substituted in position 3; R3a is hydrogen, halo, C1-6alkyloxy or C1-6alkyl; R3b is as defined above for R3;
Figure US07514445-20090407-C00023
wherein R4 is 4-pyridyl substituted in position 3; R3a is hydrogen, halo, C1-6alkyloxy or C1-6alkyl; X—R2 is as defined above;
Figure US07514445-20090407-C00024
wherein R3a is halo, cyano, C1-4alkyloxy, polyhaloC1-4alkyloxy, C1-4alkylthio, C1-4alkyl-S(═O)—, C1-4alkyl-S(═O)2—, C1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxycarbonyl, mono-or di(C1-4alkyl)aminocarbonyl, aminocarbonyl, polyhaloC1-4alkylthio; R3b is hydrogen, halo, cyano, nitro, C1-4alkyl, C1-4alkyloxy, polyhaloC1-4alkyl, C1-4alkyloxycarbonyl, C1-4alkylcarbonyl; R3c is hydrogen, halo or C1-4alkyl; R4 is 2-furanyl, 2-thienyl or 3-thienyl;
Figure US07514445-20090407-C00025
wherein R4 is pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, pyridazinyl, or imidazolyl, each of said rings optionally substituted with one or more substituents selected from halo, cyano, aminocarbonyl, —C(═O)—O—R4′, —C(═O)—R4′, —S(═O)2—NR4′R4″, NR4′R4″, —O—R4′ or C1-6alkyl optionally substituted with fluoro wherein R4′and R4″each independently represent hydrogen or C1-6alkyl optionally substituted with mono- or di(C1-6alkyl)amino; R1, R3 and s are as defined hereinabove;
Figure US07514445-20090407-C00026
wherein R4 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-methyl-3-pyridyl, 6-methyl-3-pyridyl, 2-furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 2-pyrazinyl, 2-benzofuranyl, 2-pyridyl-N-oxide, 3-pyridyl-N-oxide, 4-pyridyl-N-oxide, 1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-pyrrol-2-yl, 4-quinolinyl, 4-pyridyl methyl iodide, dimethylaminophenyl; R1 is hydrogen or C1-3alkyl; s is 1 to 3; X, R2 and R3 are as defined hereinabove.
Figure US07514445-20090407-C00027
wherein R4 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, pyridyl optionally substituted with C1-6alkyl, pyridyl N-oxide optionally substituted with C1-6alkyl; X is —O—, —NR1—C(═O)—O—, —NR1—C(═O)—, —NR1—C(═S)—, —NR1—C(═O)—NR1—, —NR1—C(═S)—NR1—or a direct bond; R2 is fluoro-substituted C1-10alkyl, optionally substituted phenyl or naphthyl, optionally substituted phenylC1-6alkyl, a monocyclic, bicyclic or tricyclic saturated carbocycle consisting of from 3 to 10 carbon atoms, a monocyclic, bicyclic or tricyclic partially saturated carbocycle consisting of from 3 to 10 carbon, C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle consisting of from 3 to 10 carbon atoms or a monocyclic, bicyclic or tricyclic partially saturated carbocycle consisting of from 3 to 10 carbon, a 5 or 6-membered heterocycle containing from 1 to 3 heteroatoms wherein the heteroatom is selected from O, N or S to which 5 or 6-membered heterocycle one or two benzene radicals may be fused, C1-6alkyl substituted by a 5 or 6-membered heterocycle containing from 1 to 3 heteroatoms wherein the heteroatom is selected from O, N or S to which 5 or 6-membered heterocycle one or two benzene radicals may be fused; R3 is nitro, R7—C(═O)—NH—; R21—C(═O)—NH—; s is as defined hereinabove.
Further preferred compounds are those compounds of formula (I) or (I′) wherein one of the following restrictions apply:
  • a) X is a direct bond and R2 is hydrogen;
  • b) R2 and R3 are other than hydrogen;
  • c) R3 is hydrogen;
  • d) Z is a direct bond.
Also preferred compounds are those compounds of formula (I) or (I′) wherein ring A is pyridyl, pyrimidinyl or pyridazinyl, in particular pyrimidinyl or pyridazinyl.
Other preferred compounds are those compounds of formula (I) or (I′) wherein ring A is pyridyl, pyrimidinyl or pyridazinyl; in particular pyrimidinyl or pyridazinyl;
  • R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl;
  • X is —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C(═S)—; —O—C(═O)—; —C(═O)—O—; —O—C(═O)—C1-6alkyl-; —C(═O)—O—C1-6alkyl-; —O—C1-6alkyl-C(═O)—; —C(═O)—C1-6alkyl-O—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —O—C(═O)—C(═O)—; —C(═O)—NR1—, —NR1—C(═O)—; —C(═S)—NR1—, —NR1—C(═S)—; —NR1—C(═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—; —C1-6alkyl-C(═O)—NR1—; —O—C1-6alkyl-C(═O)—NR1—; —C1-6alkyl-O—C(═O)—NR1—; —C1-6alkyl-; —O—C1-6alkyl-; —C1-6alkyl-O—; —NR1—C1-6alkyl-; —C1-6alkyl-NR1—; —NR1—C1-6alkyl-NR1—; —NR1—C1-6alkyl-C3-7cycloalkyl-; —C2-6alkenyl-; —C2-6alkynyl-; —O—C2-6alkenyl-; —C2-6alkenyl-O—; —NR1—C2-6alkenyl-; —C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-C3-7cycloalkyl-; —O—C2-6alkynyl-; —C2-6alkynyl-O—; —NR1—C2-6alkynyl-; —C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-C3-7cycloalkyl-; —O—C1-6alkyl-O—; —O—C2-6alkenyl-O—; —O—C2-6alkynyl-O—; —CHOH—; —S—; —S(═O)—; —S(═O)2—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —S—C1-6alkyl-; —C1-6alkyl-S—; —S—C2-6alkenyl-; —C2-6alkenyl-S—; —S—C2-6alkynyl-; —C2-6alkynyl-S—; —O—C1-6alkyl-S(═O)2— or a direct bond;
  • Z is a direct bond, C1-6alkanediyl, C2-6alkenediyl, C2-6alkynediyl; —O—; —O—C1-6alkyl-; —C(═O)—; —C(═O)—O—; —O—C(═O)—; —C(═S)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C1-6alkyl-; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —NR1—C(═S)—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —NR1—(C═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—;
  • R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C3-7cycloalkyl; R5R6N—C1-6alkyloxy; R5aR6aN—C(═O)—; R5R6N—C(═S); R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)1—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O), —NH—; R15—O—S(═O), —NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR9—Y1—; H—Y2—NR19—Y1—;
  • R3 is hydrogen; hydroxy; halo; C1-6alkyl; C1-6alkyl substituted with cyano, hydroxy or —C(═O)R7; C2-6alkenyl; C2-6alkenyl substituted with one or more halogen atoms or cyano; C2-6alkynyl; C2-6alkynyl substituted with one or more halogen atoms or cyano; C1-6alkylthio; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkylthio; R21; R21—C1-6alkyl; R21—O—; R21—S—; R21—C(═O)—; R21—S(═O)p—; R7—S(═O)p—; R7—S(═O)p—NH—; R21—S(═O)p—NH—; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2; R7—C(═O)—NH—; R21—C(═O)—NH—; —C(═NH)R7; —C(═NH)R2;
  • R4 is tetrahydrofuranyl, dihydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, pyrimidinyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, triazinyl, morpholinyl, dioxolanyl or dioxanyl, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n, —NH—; R15—O—S(═O), —NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR6—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
  • R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y1—R8, —Y, —NR9R10, or
  • R5a and R6a each independently are hydrogen, C1-6alkyl; C2-6alkenyl or C2-6alkynyl, each of said groups representing R5a and R6a may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R5 and R6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14, or each of said heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
  • R7 is C1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino or polyhaloC1-6alkyl;
  • R8 is C1-6alkyl; C2-6alkenyl; C2-6alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R9, R10 and R11 each independently are hydrogen or R8, or any two of R9, R10 and R11 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R12, R13 and R14 each independently are hydrogen; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R16N—S(═O)—; R15R16N—S(═O)2—; R17R18N—Y1—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—; oxo, or
  • any two of R12, R13 and R14 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo—or heterocycle or an aromatic 4 to 8 membered monocyclic carbo—or heterocycle together with the atoms to which they are attached, or
  • any two of R12, R13 and R14 may together be —O(CH2)r—O— thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo—or heterocycle together with the atoms to which they are attached;
  • R15 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R15 may optionally be substituted with one or more substituents selected from R12, R13 and R14; or each of said carbocycles or heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
  • R16, R17, R18 and R19 each independently are hydrogen or R17, or
  • R17 and R18, or R15 and R19 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R2, R13 and R4; or
  • R17 and R18 together with R16 may be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
  • R21 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R21 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • Y1a is —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y1 or Y2 each independently are a direct bond, —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4—, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
  • Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl;
  • n is 1 or 2;
  • m is 1 or 2;
  • p is 1 or 2;
  • r is 1 to 5;
  • s is 1 to 3;
  • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy; provided that —X—R2 and/or R3 is other than hydrogen; and provided that R4 is other than optionally substituted pyridyl when ring A represents pyrimidinyl.
Still other preferred compounds are those compounds of formula (I) or (I′) wherein ring A is pyridyl, pyrimidinyl or pyridazinyl; in particular pyrimidinyl or pyridazinyl;
  • R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl;
  • X is —NR1—; —O—; —C(═O)—; —O—C(═O)—; —C(═O)—O—; —O—C(═O)—C1-6alkyl-; —C(═O)—O—C1-6alkyl-; —O—C1-6alkyl-C(═O)—; —C(═O)—C1-6alkyl-O—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —C(═O)—NR1—, —NR1—C(═O)—; —C1-6alkyl-; —O—C1-6alkyl-; —C1-6alkyl-O—; —NR1—C1-6alkyl-; —C1-6alkyl-NR1—; —NR1—C1-6alkyl-NR1—; —C2-6alkenyl-; —C2-6alkynyl-; —O—C2-6alkenyl-; —C2-6alkenyl-O—; —NR1—C2-6alkenyl-; —C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-NR1—; —O—C2-6alkynyl-; —C2-6alkynyl-O—; —NR1—C2-6alkynyl-; —C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-NR1—; —O—C1-6alkyl-O—; —O—C2-6alkenyl-O—; —O—C2-6alkynyl-O—; —CHOH—; —S—; —S(═O)—; —S(═O)2—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —S—C1-6alkyl-; —C1-6alkyl-S—; —S—C2-6alkenyl-; —C2-6alkenyl-S—; —S—C2-6alkynyl-; —C2-6alkynyl-S—; or a direct bond;
  • Z is a direct bond, C1-6alkanediyl, C2-6alkenediyl, C2-6alkynediyl; —O—; —O—C1-6alkyl-; —C(═O)—; —C(═O)—O—; —O—C(═O)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C1-6alkyl-; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1C (═O)—O—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—;
  • R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C1-6alkyloxy; R5aR6aN—C(═O)—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═O)—NH—;
  • R3 is hydrogen; hydroxy; halo; C1-6alkyl; C1-6alkyl substituted with cyano, hydroxy or —C(═O)R7; C2-6alkenyl; C2-6alkenyl substituted with one or more halogen atoms or cyano; C2-6alkynyl; C2-6alkynyl substituted with one or more halogen atoms or cyano; C1-6alkylthio; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkylthio; R21; R21—C1-6alkyl; R21—O—; R21—S—; R21—C(═O)—; R21—S(═O)p—; R7—S(═O)p—; R7—C(═O)—; —C(═O)NHNH2; R7—C(═O)—NH—; R21—C(═O)—NH—; —C(═NH)R7; —C(═NH)R21;
  • R4 is tetrahydrofuranyl, dihydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, pyrimidinyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, triazinyl, morpholinyl, dioxolanyl or dioxanyl, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C1-6alkyloxy; R5aR6aN—C(═O)—; R5R6N—S(═O)n—; R15—C(═O)—NH—;
  • R5 and R6 each independently are hydrogen or R8;
  • R5a and R6a each independently are hydrogen, C1-6alkyl; C2-6alkenyl or C2-6alkynyl, each of said groups representing R5a and R6a may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R7 is C1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino or polyhaloC1-6alkyl;
  • R8 is C1-6alkyl; C2-6alkenyl; C2-6alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R12, R13 and R14 each independently are hydrogen; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R15R16N—S(═O)—; R15R16N—S(═O)2—;
  • R15 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said substituents representing R15 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • R16 is hydrogen or R15;
  • R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
  • R21 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R21 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
  • n is 1 or 2;
  • m is 1 or 2;
  • p is 1 or 2;
  • s is 1 to 3;
  • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy;
  • provided that —X—R2 and/or R3 is other than hydrogen; and
  • provided that R4 is other than optionally substituted pyridyl when ring A represents pyrimidinyl.
Further preferred are those compounds of formula (I) or (I′) wherein the compounds are compounds from one of the following formulae:
Figure US07514445-20090407-C00028
Also preferred are those compounds of formula (a-1) wherein one or where possible more, preferably all of the following restrictions apply:
(a) s is 1 and said R3 substituent is placed at the para position compared to the NR1 linker;
(b) s is 1 and said R3 substituent is placed at the para position of the NR1 linker and is other than C1-6alkyloxy or polyhaloC1-6alkyloxy;
(c) X is other than a direct bond or C1-6alkyl
(d) Z is other than S;
(e) X—R2 is other than hydroxy, C1-6alkyl, C1-6alkyloxy, trihalomethyl,
trihalomethyloxy, cyanoC1-6alkyl, aminocarbonyl;
(f) R4 is an optionally substituted 5-membered heterocycle with at least 2 nitrogen atoms;
(g) R2 is other than hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and X is other than O,
S, C(═O), S(═O), S(═O)2, —NH—S(═O)—, —NH—S(═O)2—, —NH—C(═O)—;
(h) R2 is other than hydrogen.
Also preferred are those compounds of formula (a-2) wherein one or more, preferably all of the following restrictions apply
(a) X is other than a direct bond or C1-6alkyl;
(b) R2 is other than hydrogen, trifluoromethyl or C1-4alkyl;
(c) X—R2 is other than hydroxy, C1-6alkyl, C1-6alkyloxy, trihalomethyl,
trihalomethyloxy, cyanoC1-6alkyl, aminocarbonyl;
(d) R4 is an optionally substituted 5-membered heterocycle.
Further interesting compounds are those compounds of formula (I), (I′), (a-1) or (a-2) wherein R4 is an optionally substituted 5-membered heterocycle, in particular an optionally substituted imidazolyl or an optionally substituted triazolyl and/or wherein Z is a direct bond.
Particular preferred compounds of formula (I) or (I′) are selected from N2-(1H-indazol-5-yl)-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine; 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-2-(phenylmethoxy)-benzonitrile; 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.
Other preferred compounds of formula (I) or (I′) are selected from N2-(6-morpholinyl-4-yl-pyridin-3-yl)-N 4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(3H-benzimidazol-5-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-indazol-6-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(5-bromo-pyridin-2-yl)-N-4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(6-methoxy-pyridin-3-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-benzothiazol-6-yl-N 4(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-indazol-5-yl)—N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-benzotriazol-5-yl)-N 4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-benzo[1,3]dioxol-5-yl-N4(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(6-chloro-pyridin-3-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-indol-5-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-quinolin-6-yl-N-4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; 4-[4-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile; 4-[4-[(quinolin-3-methyl)-amino]-pyrimidin-2-ylamino]-benzonitrile; 4-[4-[(furan-2-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile; 4-[4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino]-benzonitrile; a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.
Compounds of formula (I) can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W1 represents a suitable leaving group, such as for example a halo atom, e.g. chloro, bromo and the like, in the presence of a suitable solvent, such as for example N N-dimethylacetamide, acetonitrile, tetrahydrofuran, water, an alcohol, e.g. methanol, ethanol, isopropanol and the like, and optionally in the presence of a suitable acid, such as for example hydrochloric acid and the like.
Figure US07514445-20090407-C00029
Alternatively, the above reaction may also be performed in the presence of a suitable solvent, such as for example toluene, a suitable catalyst, such as tris (dibenzylidene aceton)dipalladium (0), a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1′-binaphthyl, and a suitable base, such as for example sodium tert.butoxide.
Compounds of formula (I) can also be prepared by reacting an intermediate of formula (IV) wherein W2 represents a suitable leaving group, such as for example a halo atom, e.g. chloro and the like, with an intermediate of formula (V) in the presence of a suitable solvent, such as for example toluene, a suitable catalyst, such as tris (dibenzylidene aceton)dipalladium (0), a suitable ligand such as for example 2,2-bis(diphenylphosphino)-1,1′-binaphthyl, and a suitable base, such as for example sodium tert.butoxide.
Figure US07514445-20090407-C00030
Compounds of formula (I) may also be prepared by reacting an intermediate of formula (VI), wherein W3 represents a suitable leaving group, such as a halo atom, e.g. chloro and the like, with an intermediate of formula (VII) in the presence of a suitable solvent, such as 1,4-dioxane or an alcohol, e.g. methanol, ethanol, isopropanol and the like, or water, optionally in the presence of a suitable acid, such as hydrochloric acid and the like, or a suitable base, such as for example N,N-diisopropylethanamine.
Figure US07514445-20090407-C00031
Compounds of formula (I) wherein Z is C(═O), said compounds being represented by formula (I-a), may be prepared by reacting an intermediate of formula (VIII), wherein W4 represents a suitable leaving group, such as a halo atom, e.g. chloro and the like, or an alcoholate, such as methanolate, ethanolate and the like, with an intermediate of formula (IX) in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like.
Figure US07514445-20090407-C00032
Compounds of formula (I) wherein Z is a direct bond, said compounds being represented by formula (I-b), can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (X) in the presence of a suitable catalyst, such as for example palladium tetrakis(triphenylphosphine), a suitable base, such as for example disodium carbonate, and a suitable solvent, such as for example acetonitrile and water.
Figure US07514445-20090407-C00033
Compounds of formula (I) wherein Z is a direct bond and R4 represents 5-tetrazolyl, said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (XI) with sodium azide in the presence of a suitable salt, such as for example N,N-diethylethanamine hydrochloric acid salt, and a suitable solvent, such as for example 1-methyl-2-pyrrolidinone.
Figure US07514445-20090407-C00034
Compounds of formula (I) wherein Z is a direct bond and ring A is pyrimidinyl with the NR1 linker placed in position 2, said compounds being represented by formula (I-d), may be prepared by reacting an intermediate of formula (XX) with an intermediate of formula (XXI) in the presence of a suitable solvent, such as for example N,N-dimethylacetamide and a suitable base, such as for example sodium ethanolate.
Figure US07514445-20090407-C00035
In the above reaction, if R4 in a compound of formula (I-d) represents a heterocycle substituted with amino are aminocarbonyl, than R4 in an intermediate of formula (XXI) may represent a heterocycle substituted with —N═CH—N(CU3)2 or —C(═O)—N═CH—N(CH3)2.
In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.
The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
The compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarbo-peroxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
Compounds of formula (I) wherein R3 is halo, or wherein R2 is substituted with halo, can be converted into a compound of formula (I) wherein R3 is cyano, or wherein R2 is substituted with cyano, by reaction with a suitable cyano-introducing agent, such as sodium cyanide or CuCN, optionally in the presence of a suitable catalyst, such as for example tetrakis(triphenylphosphine)palladium and a suitable solvent, such as N,N-dimethylacetamide or N,N-dimethylformamide. A compound of formula (I) wherein R3 is cyano, or wherein R2 is substituted with cyano, can further be converted into a compound of formula (I) wherein R3 is aminocarbonyl, or wherein R1 is substituted with aminocarbonyl, by reaction with HCOOH, in the presence of a suitable acid, such as hydrochloric acid. A compound of formula (I) wherein R3 is cyano, or wherein R2 is substituted with cyano, can also further be converted into a compound of formula (I) wherein R3 is tetrazolyl, or wherein R2 is substituted with tetrazolyl, by reaction with sodium azide in the presence of ammonium chloride and N,N-dimethylacetoacetamide.
Compounds of formula (I) wherein R2 is substituted with halo, can also be converted into a compound of formula (I) wherein R2 is substituted with mercapto, by reaction with disodium sulfide in the presence of a suitable solvent, such as, for example, 1,4-dioxane.
Compounds of formula (I) wherein R2 is substituted with halo, can also be converted into a compound of formula (I) wherein R2 is substituted with C1-6alkylthio, by reaction with a reagent of formula alkaline metal+−S—C1-6alkyl e.g. Na+ −S—C1-6alkyl in the presence of a suitable solvent, such as dimethylsulfoxide. The latter compounds can further be converted into a compound of formula (I) wherein R2 is substituted with C1-6alkyl-S(═O)—, by reaction with a suitable oxidizing agent, such as a peroxide, e.g. 3-chlorobenzenecarboperoxoic acid, in the presence of a suitable solvent, such as an alcohol, e.g. ethanol.
Compounds of formula (I) wherein R3 is halo, or wherein R2 is substituted with halo, can also be converted into a compound of formula (I) wherein R3 is C1-6alkyloxy, or wherein R2 is substituted with C1-6alkyloxy, by reaction with alcoholate salt, such as, for example, LiOC1-6alkyl, in the presence of a suitable solvent, such as an alcohol, e.g. methanol.
Compounds of formula (I) wherein R3 is halo, or wherein R2 is substituted with halo, can also be converted into a compound of formula (I) wherein R3 is hydroxy, or wherein R2 is substituted with hydroxy, by reaction with a suitable carboxylate, e.g. sodium acetate, in a suitable reaction-inert solvent, such as, for example, dimethylsulfoxide, followed by treating the obtained reaction product with a suitable base, such as pyridine, and acetyl chloride.
Compounds of formula (I) wherein R3 is halo, or wherein R2 is substituted with halo, can also be converted into a compound of formula (I) wherein R3 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, or wherein R2 is substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, said substituents being represented by -L, by reaction with H-L in the presence of a suitable base, such as for example sodium hydroxide, dipotassium carbonate, sodium hydride, in the presence of a suitable solvent, such as, for example, 1,4-dioxane, N,N-dimethylacetamide, N,N-dimethylformamide.
Compounds of formula (I) wherein R3 is chloro, or wherein R2 is substituted with chloro, can be converted into a compound of formula (I) wherein R3 is fluoro, or wherein R2 is substituted with fluoro, by reaction with a suitable fluoride salt, such as for example potassium fluoride, in the presence of a suitable solvent, e.g. sulfolane.
Compounds of formula (I) wherein X—R2 is hydrogen and wherein the R3 substituent positioned at the meta position compared to the NR1 linker, is halo, can be converted into a compound of formula (I) wherein said R3 substituent is replaced by X—R2 wherein X is other than a direct bond when R2 is hydrogen, by reaction with H—X—R2 in the presence of a suitable solvent, such as N,N-dimethylacetamide or N,N-dimethylformamide optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine.
Compounds of formula (I) wherein R2 is substituted with C1-4alkyloxyC1-6alkyl, can be converted into a compound of formula (I) wherein R2 is substituted with hydroxyC1-6alkyl, by dealkylating the ether in the presence of a suitable dealkylating agent, such as, for example, tribromoborane, and a suitable solvent, such as methylene chloride.
Compounds of formula (I) wherein R3 or X—R2 are C1-6alkyloxycarbonyl, or wherein R2 is substituted with C1-6alkyloxycarbonyl, can be converted into a compound of formula (I) wherein R3 or X—R2 are aminocarbonyl, or wherein R2 is substituted with aminocarbonyl or mono- or di(C1-6alkyl)aminocarbonyl, by reaction with a suitable agent such as ammonia, NH2(C1-6alkyl), AlCH3[N(C1-6alkyl)2]Cl optionally in the presence of a suitable acid, such as for example hydrochloric acid, and in the presence of a suitable solvent such as an alcohol, e.g. methanol; tetrahydrofuran; N,N-diisopropylethane.
Compounds of formula (I) wherein R3 is hydrogen or wherein R2 is unsubstituted, can be converted into a compound wherein R3 is halo or wherein R2 is substituted with halo, by reaction with a suitable halogenating agent, such as, for example Br2 or 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2,2,2]octane bis[tetrafluoroborate], in the presence of a suitable solvent, such as tetrahydrofuran, water, acetonitrile, chloroform and optionally in the presence of a suitable base such as N,N-diethylethanamine.
Compounds of formula (I) wherein R3 or —X—R2 are C1-6alkyloxycarbonyl or wherein R2 is substituted with C1-6alkyloxycarbonyl, can be converted into a compound of formula (I) wherein R3 or X—R2 are hydroxymethyl or wherein R2 is substituted with hydroxymethyl, by reaction with a suitable reducing agent, such as for example LiAlH4.
Compounds of formula (I) wherein —X—R2 is —O—CH2— (optionally substituted)phenyl may be converted into a compound of formula (I) wherein —X—R2 represents OH, by reaction with a suitable reducing agent, such as H2, in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like, or N,N-dimethylacetamide.
Compounds of formula (I) wherein —X—R2 represents OH, may be converted into a compound of formula (I) wherein —X—R2 represents —O—X1—R2, by reaction with W1—X1—R2 wherein W1 represents a suitable leaving group, such as for example a halo atom, e.g. chloro, and wherein —O—X1 represents those linkers falling under the definition of X which are attached to the phenyl ring via a O atom (in said definition X1 represents that part of the linker wherein the O atom is not included), in the presence of a suitable base, such as for example dipotassium carbonate, and a suitable solvent, such as for example N,N-dimethylacetamide.
Compounds of formula (I) wherein R3 is nitro, or wherein R2 is substituted with nitro, may be converted into a compound of formula (I) wherein R3 is amino or wherein R2 is substituted with amino, by reaction with a suitable reducing agent, such as for example H2, in the presence of a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol and the like.
Compounds of formula (I) wherein R2 is substituted with NH2, can be converted into a compound of formula (I) wherein R2 is substituted with NH—S(═O)2—NR5R6, by reaction with W1—S(═O)2—NR5R6 wherein W1 represents a suitable leaving group such as for example a halo atom, e.g. chloro, in the presence of a suitable solvent, such as for example N,N-dimethylacetamide and a suitable base, such as for example N,N-diethylethanamine.
Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures, such as those described in WO 99/50250, WO 00/27825 or EP 0,834,507.
Intermediates of formula (II) wherein R1 is hydrogen, said intermediates being represented by formula (II-a), can be prepared by reducing an intermediate of formula (XII) in the presence of a suitable reducing agent, such as for example H2, a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol, ethanol and the like.
Figure US07514445-20090407-C00036
Intermediates of formula (III) can be prepared by reacting an intermediate of formula (XIII) wherein W1 is as defined hereinabove, with an intermediate of formula (XIV) in the presence of a suitable solvent, such as for example acetonitrile or dioxane, and optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine.
Figure US07514445-20090407-C00037
Intermediates of formula (IV) can be prepared by reacting an intermediate of formula (XV) wherein W2 is as defined hereinabove, with an intermediate of formula (XVI) wherein W2 is as defined hereinabove.
Figure US07514445-20090407-C00038
Intermediates of formula (XVI) can be prepared by reacting an intermediate of formula (XVII) with a leaving group introducing agent of formula (XVIII) wherein W2 represents the leaving group and R represents the remaining of the leaving group introducing agent, such as for example POCl3.
Figure US07514445-20090407-C00039
Intermediates of formula (VI) can be prepared by reacting an intermediate of formula (XIX) wherein W3 is as defined hereinabove, with an intermediate of formula (III) in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, ethanol, isopropanol and the like, and a suitable acid, such as for example hydrochloric acid.
Figure US07514445-20090407-C00040
Intermediates of formula (VIII) wherein ring A is pyrimidinyl with the NR1 linker in position 2 and W4 represents an alcoholate, i.e. C1-6alkylO—, said intermediates being represented by formula (VIII-a), may be prepared by reacting an intermediate of formula (XX) with an intermediate of formula (XXII) in the presence of a suitable solvent, such as for example N,N-dimethylacetamide.
Figure US07514445-20090407-C00041
Intermediates of formula (XXII) can be prepared by reacting an intermediate of formula (XXIII) with 1,1-diethoxy-N,N-dimethyl-methanamine.
Figure US07514445-20090407-C00042
Intermediates of formula (XX) can be prepared by reacting an intermediate of formula (V) with cyanamide in the presence of a suitable solvent, such as for example diglyme.
Figure US07514445-20090407-C00043
Intermediates of formula (XXI) can be prepared by reacting an intermediate of formula (XXIV) with 1,1-diethoxy-N,N-dimethyl-methanamine.
Figure US07514445-20090407-C00044
The compounds of formula (I) or (I′) inhibit Glycogen synthase kinase 3 (GSK3), in particular glycogen synthase kinase 3 beta (GSK3β). They are selective Glycogen synthase kinase 3 inhibitors. Specific inhibitory compounds are superior therapeutic agents since they are characterized by a greater efficacy and lower toxicity by virtue of their specificity.
Synonyms for GSK3 are tau protein kinase I (TPK I), FA (Factor A) kinase, kinase FA and ATP-citrate lysase kinase (ACLK).
Glycogen synthase kinase 3 (GSK3), which exists in two isoforms, i.e. GSK3α and GSK3β, is a proline-directed serine/threonine kinase originally identified as an enzyme that phosphorylates glycogen synthase. However, it has been demonstrated that GSK3 phosphorylates numerous proteins in vitro such as glycogen synthase, phosphatase inhibitor I-2, the type-II subunit of cAMP-dependent protein kinase, the G-subunit of phosphatase-1, ATP-citrate lyase, acetyl coenzyme A carboxylase, myelin basic protein, a microtubule-associated protein, a neurofilament protein, an N-CAM cell adhesion molecule, nerve growth factor receptor, c-Jun transcription factor, JunD transcription factor, c-Myb transcription factor, c-Myc transcription factor, L-Myc transcription factor, adenomatous polyposis coli tumor supressor protein, tau protein and β-catenin.
The above-indicated diversity of proteins which may be phosphorylated by GSK3 implies that GSK3 is implicated in numerous metabolic and regulatory processes in cells.
GSK3 inhibitors may therefore be useful in the prevention or treatment of diseases mediated through GSK3 activity such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, cancer, dermatological disorders such as baldness, neuronal damage, schizophrenia, pain, in particular neuropathic pain. GSK3 inhibitors can also be used to inhibit sperm motility and can therefore be used as male contraceptives.
In particular, the compounds of the present invention are useful in the prevention or treatment of Alzheimer's disease, diabetes, especially type 2 diabetes (non insulin dependent diabetes).
The major neuropathological landmarks in Alzheimer's disease are neuronal loss, the deposition of amyloid fibers and paired helical filaments (PHF) or neurofibrillary tangles (NFT). Tangle formation appears to be the consequence of accumulation of aberrantly phosphorylated tau protein. This aberrant phosphorylation destabilizes neuronal cytoskeleton, which leads to reduced axonal transport, deficient functioning and ultimately neuronal death. The density of neurofibrillary tangles has been shown to parallel duration and severity of Alzheimer's disease. Reduction of the degree of tau phosphorylation can provide for neuroprotection and can prevent or treat Alzheimer's disease or can slow the progression of the disease. As mentioned hereinabove, GSK3 phosphorylates tau protein. Thus compounds having an inhibitory activity for GSK3 may be useful for the prevention or the treatment of Alzheimer's disease.
Insulin regulates the synthesis of the storage polysaccharide glycogen. The rate-limiting step in the glycogen synthesis is catalyzed by the enzym glycogen synthase. It is believed that glycogen synthase is inhibited by phosphorylation and that insulin stimulates glycogen synthase by causing a net decrease in the phosphorylation of this enzym. Thus, in order to activate glycogen synthase, insulin must either activate phosphatases or inhibit kinases, or both.
It is believed that glycogen synthase is a substrate for glycogen synthase kinase 3 and that insulin inactivates GSK3 thereby promoting the dephosphorylation of glycogen synthase.
In addition to the role of GSK3 in insulin-induced glycogen synthesis, GSK3 may also play a role in insulin resistance. It is believed that GSK3 dependent Insulin Receptor Substrate-1 phosphorylation contributes to insulin resistance.
Therefore, GSK3 inhibition may result in the increased deposition of glycogen and a concomitant reduction of blood glucose, thus mimicing the hypoglycemic effect of insulin. GSK3 inhibition provides an alternative therapy to manage insulin resistance commonly observed in non insulin dependent diabetes mellitus and obesity. GSK3 inhibitors may thus provide a novel modality for the treatment of type 1 and type 2 diabetes.
GSK3 inhibitors, in particular GSK3β inhibitors, may also be indicated for use in the prevention or the treatment of pain, in particular neuropathic pain.
After axotomy or CCI, neuronal cells die through an apoptotic pathway and the morphological changes correlate with the onset of hyperalgesia and/or allodynia. The induction of apoptosis is probably triggered by a reduced supply of neurotrophic factors as the time course of neuronal loss is positively altered by administration of neurotrophins. GSK, in particular GSK3β, has been shown to be involved in the initiation of the apoptotic cascade and trophic factor withdrawal stimulates the GSK3β apoptosis pathway.
In view of the above, GSK3β inhibitors might reduce signals of and even prevent levels of neuropathic pain.
Due to their GSK3 inhibitory properties, particularly their GSK3β inhibitory properties, the compounds of formula (I) or (I′), their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, are useful to prevent or treat GSK3 mediated diseases, in particular GSK3β mediated diseases, such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, cancer, dermatological disorders such as baldness, neuronal damage, schizophrenia, pain, in particular neuropathic pain. The present compounds are also useful as male contraceptives. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from disease mediated through GSK3, in particular GSK3β, or they may be useful to prevent warm-blooded animals to suffer from disease mediated through GSK3, in particular GSK3 β. More in particular, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder.
In view of the above described pharmacological properties, the compounds of formula (I) or any subgroup thereof, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms, may be used as a medicine. In particular, the present compounds can be used for the manufacture of a medicament for treating or preventing diseases mediated through GSK3, in particular GSK3β. More in particular, the present compounds can be used for the manufacture of a medicament for treating or preventing Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder.
In view of the utility of the compounds of formula (I) or (I′), there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from diseases mediated through GSK3, in particular GSK3β, more in particular a method of treating or preventing Alzheimer's disease, diabetes, especially type 2 diabetes, cancer, inflammatory diseases or bipolar disorder. Said method comprises the administration, preferably oral administration, of an effective amount of a compound of formula (I) or (I′), a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.
The present invention also provides compositions for preventing or treating diseases mediated through GSK3, in particular GSK3β, comprising a therapeutically effective amount of a compound of formula (I) or (I′) and a pharmaceutically acceptable carrier or diluent.
The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
The present compounds are orally active compounds, and are preferably orally administered.
The exact dosage, the therapeutically effective amount and frequency of administration depends on the particular compound of formula (I) or (I′) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
When used as a medicament to prevent or treat Alzheimer's disease, the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat Alzheimer's disease, such as galantamine, donepezil, rivastigmine or tacrine. Thus, the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating Alzheimer's disease. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating Alzheimer's disease, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of Alzheimer's disease. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat type 2 diabetes, the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat type 2 diabetes, such as glibenclamide, chlorpropamide, gliclazide, glipizide, gliquidon, tolbutamide, metformin, acarbose, miglitol, nateglinide, repaglinide, acetohexamide, glimepiride, glyburide, tolazamide, troglitazone, rosiglitazone, pioglitazone, isaglitazone.
Thus, the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating type 2 diabetes. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating type 2 diabetes, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of type 2 diabetes. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat cancer, the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat cancer such as platinum coordination compounds for example cisplatin or carboplatin; taxane compounds for example paclitaxel or docetaxel; camptothecin compounds for example irinotecan or topotecan; anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine; anti-tumour nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine; nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine; anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 antibodies for example trastzumab; and anti-tumour podophyllotoxin derivatives for example etoposide or teniposide; and antiestrogen agents including estrogen receptor antagonists or selective estrogen receptor modulators preferably tamoxifen, or alternatively toremifene, droloxifene, faslodex and raloxifene; aromatase inhibitors such as exemestane, anastrozole, letrazole and vorozole; differentiating agents for example retinoids, vitamin D and DNA methyl transferase inhibitors for example azacytidine; kinase inhibitors for example flavoperidol and imatinib mesylate or farnesyltransferase inhibitors for example R115777.
Thus, the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating cancer. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating cancer, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of cancer. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat bipolar disorder, the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat bipolar disorder such as atypical antipsychotics, anti-epileptica, benzodiazepines, lithium salts, for example olanzapine, risperidone, carbamazepine, valproate, topiramate.
Thus, the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating bipolar disorder. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating bipolar disorder, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of bipolar disorder. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat inflammatory diseases, the compounds of formula (I) or (I′) may be used in combination with other conventional drugs used to combat inflammatory diseases such as steroids, cyclooxygenase-2 inhibitors, non-steroidal-anti-inflammatory drugs, TNF-α antibodies, such as for example acetyl salicylic acid, bufexamac, diclofenac potassium, sulindac, diclofenac sodium, ketorolac trometamol, tolmetine, ibuprofen, naproxen, naproxen sodium, tiaprofen acid, flurbiprofen, mefenamic acid, nifluminic acid, meclofenamate, indomethacin, proglumetacine, ketoprofen, nabumetone, paracetamol, piroxicam, tenoxicam, nimesulide, fenylbutazon, tramadol, beclomethasone dipropionate, betamethasone, beclamethasone, budesonide, fluticasone, mometasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, celecoxib, rofecoxib, infliximab, leflunomide, etanercept, CPH 82, methotrexate, sulfasalazine.
Thus, the present invention also relates to the combination of a compound of formula (I) or (I′) and another agent capable of preventing or treating inflammatory diseases. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I) or (I′), and (b) another agent capable of preventing or treating inflammatory diseases, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of inflammatory disorders. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
Experimental Part
Hereinafter, “DIPE” is defined as diisopropyl ether, “DMA” is defined as N,N-dimethylacetamide, “DMF” is defined as N,N-dimethylformamide.
A. Preparation of the Intermediate Compounds
EXAMPLE A1
Reaction under Argon atmosphere. 2,4,6-Trimethylaniline (0.0678 mol) was added to 2,4-dichloropyrimidine (0.0664 mol) in 1,4-dioxane (100 ml). N,N-di(1-methylethyl)-ethaneamine (N,N-diisopropylethanamine) (0.0830 mol) was added. The reaction mixture was stirred and refluxed for 4 days and the solvent was evaporated. The residue was dissolved in CH2Cl2, washed with a saturated NaHCO3 solution, then dried (Na2SO4), filtered and the solvent was evaporated to give 17.1 g solid residue. This solid was dissolved in CH2Cl2:hexane (1:1; 150 ml), and the resulting solution was concentrated to 100 ml, then filtered. The residue was purified by column chromatography on KP-Sil (eluent: CH2Cl2). The desired fractions were collected and the solvent was evaporated. The less polar fraction was stirred in CH2Cl2 for 3 hours and filtered, yielding 0.44 g 4-chloro-N-(2,4,6-trimethylphenyl)-2-pyrimidinamine. A second fraction was recrystallized from acetonitrile, filtered off and dried, yielding 2-chloro-N-(2,4,6-trimethyl-phenyl)-4-pyrimidinamine (intermediate 1).
EXAMPLE A2
A mixture of 4-[(4-hydroxy-2-pyrimidinyl)amino]-benzonitrile (0.12 mol) in POCl3 (90 ml) was stirred and refluxed under Argon for 20 minutes. The reaction mixture was slowly poured onto 750 ml ice/water, and the solid was separated by filtration. The solid was suspended in 500 ml water, and the pH of the suspension was adjusted to neutral by adding a 20% NaOH solution. The solid was again separated by filtration, suspended in 200 ml 2-propanone, and 1 L methylene chloride was added. The mixture was heated till all solid had dissolved. After cooling to room temperature, the aqueous layer was separated, and the organic layer was dried over magnesium sulfate. During removal of the drying agent by filtration, a solid formed in the filtrate. Further cooling of the filtrate in the freezer, followed by filtration, yielded 21.38 g of 4-[(4-chloro-2-pyrimidinyl)amino]-benzonitrile (intermediate 2).
EXAMPLE A3
a) The Preparation of Intermediate 3
Figure US07514445-20090407-C00045
A mixture of 4-amino-2-(2-phenylethoxy)benzonitrile (0.012 mol) in 1,1′-oxybis [2-methoxyethane] (50 ml) was stirred at 100° C., cyanamide (1 ml) was added dropwise. The reaction mixture was stirred at 100° C. for 30 minutes and at room temperature overnight. Extra cyanamide (1 ml) was added and the reaction mixture was stirred at 100° C. for 24 hours. Extra cyanamide (1 ml) was added and the reaction mixture was stirred further at 100° C. for 24 hours. The solvent was evaporated. The residue (6.3 g) was purified by high-performance liquid chromatography over Hyperprep C18 HS BDS (eluent: (0.5% NH4Ac in H2O/CH3CN 90/10)/MeOH/CH3CN 75/25/0; 0/50/50; 0/0/100). The first fraction was collected and the solvent was evaporated, yielding 1.36 g (42.6%) of intermediate 3.
b) The Preparation of Intermediate 4
Figure US07514445-20090407-C00046
Cyanamide (0.0444 mol) was added portionwise at 80° C. to a solution of 4-amino-2-(phenylmethoxy)-benzonitrile hydrochloric acid (1:1) (0.0444 mol) in 1,1′-oxybis[2-methoxyethane] (90 ml). The mixture was stirred at 100° C. for 3 hours, cooled to room temperature and poured out into ice water. The precipitate was filtered. The filtrate was evaporated. The residue was taken up in CH2Cl2 and crystallized. The precipitate was filtered off and dried, yielding 12.5 g of intermediate 4 (90%) 9 mp. 132° C.).
EXAMPLE A4
a) The Preparation of Intermediate 5
Figure US07514445-20090407-C00047
1,1-Diethoxy-N,N-dimethylmethanamine (0.153 mol) was added over 15 minutes to ethyl 2-oxopropanoate (0.153 mol) at room temperature while vigorously stirring. The temperature was kept below 30° C. The reaction mixture was heated to 80° C. for 24 hours. The residue was purified by distillation, yielding 9.8 g (37.4%) of intermediate 5.
EXAMPLE A5
The Preparation of Intermediate 6
Figure US07514445-20090407-C00048
To a solution of intermediate 3 (0.00477 mol) in DMA (30 ml), intermediate 5 (0.0057 mol) was added. The reaction mixture was stirred for 1 hour at room temperature and overnight at 100° C. This mixture was again stirred at 100° C. for 24 hours and then cooled to room temperature. The residue was poured out in a saturated NaCl-solution (300 ml), filtered and washed with H2O. The precipitate was dissolved in 2-propanone and this solution was concentrated in vacuum. The obtained solid was crystallized from EtOH, filtered and dried at 40° C. under vacuum, yielding 0.64 g (35.8%) of intermediate 6.
EXAMPLE A6
a) The Preparation of Intermediate 7
Figure US07514445-20090407-C00049
1-(1-Methyl-1H-imidazol-2-yl)ethanone (0.0028 mol) in 1,1-diethoxy-N,N-dimethylmethanamine (10 ml) was stirred and refluxed for 12 hours; then allowed to cool to room temperature. The precipitate was filtered off and dried (50° C., vacuum), yielding 0.42 g (82.3%) of intermediate 7.
b) The Preparation of Intermediate 8
Figure US07514445-20090407-C00050
A mixture of 5-acetyl-3-pyridinecarboxamide in DMF/DMA (100 ml) was stirred at 80° C. overnight. The precipitate was filtered off and dried (vacuum), yielding 4 g of intermediate 8.
B. Preparation of the Final Compounds
EXAMPLE B1
The Preparation of Compound 1
Figure US07514445-20090407-C00051
A suspension of 6-bromo-2,3′-bipyridine (0.00042 mol), tris (dibenzylidene aceton)dipalladium (0) (0.0085 mmol), 2,2-bis(diphenylphosphino)-1,1′-binaphthyl (0.0128 mmol) and sodium tert. butoxide (0.00051 mol) in toluene (4 ml) was degassed with N2. 3-(Trifluoromethyl)-benzenamine (0.00051 mol) was added while stirring at room temperature. The resulting reaction mixture was stirred for 18 hours at 90° C. The reaction mixture was washed with water (1 ml), then filtered through Extrelut and the filtrate was evaporated, yielding 0.027 g of compound 1.
EXAMPLE B2
a) The Preparation of Compound 2
Figure US07514445-20090407-C00052
A mixture of methanol (4 ml), water (4 ml) and HCl/2-propanol (0.2 ml) was added to a mixture of intermediate 2 (0.000242 mol) and 1H-indazol-5-amine (0.000242 mol). The reaction mixture was stirred overnight at 60° C. The desired compound was isolated and purified by high performance liquid chromatography over RP C-18 (eluent: (0.5% NH4OAc in H2O/CH3CN 90/10)/CH3OH/CH3CN 70/15/15; 0/50/50; 0/0/100). The desired fractions were collected and the solvent was evaporated, yielding 0.017 g of compound 2.
b) The Preparation of Compound 3
Figure US07514445-20090407-C00053
A mixture of intermediate 2 (0.000325 mol), 3-quinolinemethanamine (0.000357 mol) and N,N-diisopropylethanamine (0.0005 mmol) in 1,4-dioxane (4 ml) was stirred at 95° C. for 3 days. The solvent was evaporated and the residue was taken up in methylene chloride. Water (1 ml) was added. The mixture was stirred for 30 minutes; then extracted through Extrelut. The Extrelut was washed twice with methylene chloride. The extract was purified by high performance liquid chromatography over silica gel (eluent: methylene chloride/methanol 100/0; 90/10). The desired fractions were collected and the solvent was evaporated, yielding 0.048 g of compound 3.
EXAMPLE B3
b) The Preparation of Compound 4
Figure US07514445-20090407-C00054
A mixture of intermediate 6 (0.002 mol) and piperazine (0.002 mol) in methanol (15 ml) was stirred at room temperature for 1 day; then stirred at 50° C. for 1 day. The solvent was evaporated. The residue was dissolved in CH2Cl2/MeOH (95/5) and washed with H2O. The separated organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH2Cl2/MeOH 92.5/7.5). The desired fractions were collected and the solvent was evaporated. The residue was stirred in diethyl ether. The precipitate was filtered off, washed and dried (50° C., vacuum), yielding 0.32 g of compound 4.
EXAMPLE B4
d) The Preparation of Compound 5
Figure US07514445-20090407-C00055
A mixture of 6-chloro-N-(2,3-dichlorophenyl)-3-pyridazinamine (0.00037 mol) and palladium tetrakis(triphenylphosphine) (0.000018 mol) in acetonitrile (10 ml) was stirred (and degassed) under N2 atmosphere and heated to 90° C. A solution of 3-pyridinylboronic acid (2 equiv, 0.00074 mol) in 0.4 M Na2CO3 in H2O (10 ml) (previously degassed under N2) was added dropwise and the resulting reaction mixture was stirred for 18 hours under N2 atmosphere. The mixture was filtered warm and the filter residue was washed with CH3CN (1 ml). The filtrate was diluted with CH2Cl2 (4 ml), then filtered/dried through Extrelut and the filtrate was evaporated. The residue was purified by preparative column chromatography. The product fractions were collected and the solvent was evaporated, yielding 0.027 g of compound 5.
Example B5
a) The Preparation of Compound 6
Figure US07514445-20090407-C00056
NaOEt (0.68 g) was added to a solution of intermediate 4 (0.01 mol) in DMA (25 ml). The reaction mixture was stirred at room temperature for 1 hour. Intermediate 4 (0.01 mol) was dissolved in DMA (5 ml) and EtOH (15 ml). This solution was added dropwise to the reaction mixture at room temperature. The mixture was stirred at room temperature for 2 hours; then gently heated to 100° C. and stirred for 3 days at this temperature. This fraction was purified by high performance liquid chromatography over hyperprep C18 (0.5% NH4OAc in H2O/CH3CN 90/10)/CH3CN 63/37; 25/75; 0/100). The desired fractions were collected and the solvent was evaporated. The residue was suspended in DIPE and stirred overnight. The precipitate was filtered off and dried (40° C., vacuum), yielding 1.34 g (35%) of compound 6.
b) The Preparation of Compound 37′ N
Figure US07514445-20090407-C00057
A mixture of guanidine, [3-(trifluoromethyl)phenyl]-, mononitrate (250 mg), intermediate 8 (220 mg), sodium methanolate (0.05 g) and methoxyethanol (20 ml) was stirred at 110° C. for 1 day. The temperature was raised to 160° C. overnight. The reaction mixture was colled, the solvent was evaporated and the residue was suspended in aceton. The precipitate was filtered off, washed and dried (vacuum), yielding 248,1 mg of compound 37.
Example B6
The Preparation of Compound 7
Figure US07514445-20090407-C00058
(compound 8) (0.013 mol) (prepared according to Example B5) in methanol and DMA (50 ml) was hydrogenated at 50° C. with Pd/C 10% (1 g) as a catalyst. After uptake of hydrogen (1 equiv), the catalyst was filtered off and the mixture was concentrated till 100 ml. The formed precipitate was filtered off, washed with DIPE and dried, yielding 2.6 g of compound 7.
Tables 1 to 4 list the compounds of formula (I) which were prepared according to one above examples.
TABLE 1
Figure US07514445-20090407-C00059
Co. No. Ex. No. R4 Physical data
9 B2a
Figure US07514445-20090407-C00060
10 B2a 1H-benzimidazol-5-yl
11 B2a 1H-indazol-6-yl
12 B2a 5-bromo-2-pyrimidinyl H20( 1:1)
13 B2a 5-bromo-2-pyridinyl
14 B2a 6-methoxy-3-pyridinyl
15 B2a 6-benzothiazolyl
2 B2a 1H-indazol-5-yl
16 B2a 1H-benzotriazol-5-yl
17 B2a 1,3-benzodioxol-5-yl
18 B2a 6-chloro-3-pyridinyl
19 B2a 1H-indol-5-yl
20 B2a 6-guinolinyl
TABLE 2
Figure US07514445-20090407-C00061
Co. No. Ex. No. R4 Z
21 B2b 2-tetrahydrofuranyl —CH2—NH—
22 B2b 2-thienyl —CH2—NH—
23 B2b
Figure US07514445-20090407-C00062
 		—CH2—NH—
24 B2b 2,2-dimethyl-1,3-dioxolan-4-yl —CH2—NH—
25 B2b 1-ethylpyrrolidin-2-yl —CH2—NH—
26 B2b 2-furanyl —CH2—NH—
3 B2b 3-quinolinyl —CH2—NH—
27 B2b
Figure US07514445-20090407-C00063
 		—CH2—NH—
28 B2b 4-morpholinyl —(CH2)2—NH—
29 B2b 1,3-benzodioxol-5-yl —CH2—NH—
30 B2b 4-methyl-1-piperazinyl direct bond
31 B2b
Figure US07514445-20090407-C00064
 		direct bond
32 B2b 4-morpholinyl direct bond
33 B5a 1-methyl-1H-imidazol-2-yl direct bond
TABLE 3
Figure US07514445-20090407-C00065
Co. No. Ex. No. R4
Figure US07514445-20090407-C00066
 		R3a R3b Physical data
34
Figure US07514445-20090407-C00067
Figure US07514445-20090407-C00068
 		4-C6H13 H
5 B4 3-pyridinyl
Figure US07514445-20090407-C00069
 		2-Cl 3-Cl
35 B4 3-pyridinyl
Figure US07514445-20090407-C00070
 		3-CF3 H
1 B1 3-pyridinyl
Figure US07514445-20090407-C00071
 		3-CF3 H
36 B5b
Figure US07514445-20090407-C00072
Figure US07514445-20090407-C00073
 		3-CF3 H
37 B5b
Figure US07514445-20090407-C00074
Figure US07514445-20090407-C00075
 		3-CF3 H
TABLE 4
Figure US07514445-20090407-C00076
Co. No. Ex. No. R4 Z X-R2 R3 Physical data
6 B5a
Figure US07514445-20090407-C00077
 		db* —O—CH2—C6H5 4-CN
4 B3 1-piperazinyl —(C═O)— —O—CH2—C6H5 4-CN
8 B5a
Figure US07514445-20090407-C00078
 		db* —O—CH2—C6H5 H
7 B6
Figure US07514445-20090407-C00079
 		db* —O—H H
*db = direct bond

C. Pharmacological Example
The pharmacological activity of the present compounds was examined using the following test.
GSK3beta assays were performed at 25° C. in a 100 μl reaction volume of 25 mM Tris (pH 7.4) containing 10 mM MgCl2, 1 mM DTT, 0.1 mg/ml BSA, 5% glycerol and containing 19 nM GSK3β, 5 μM biotinylated phosphorylated CREB peptide, 1 μM ATP, 2 nM ATP-P33 and a suitable amount of a test compound of formula (I) or (I′). After one hour, the reaction was terminated by adding 70 μl of Stop mix (1 mM ATP, 18 mg/ml streptavidin coated PVT SPA bead pH 11.0). The beads to which the phosphorylated CREB peptide is attached were allowed to settle for 30 minutes and the radioactivity of the beads was counted in a microtiterplate scintillation counter and compared with the results obtained in a control experiment (without the presence of a test compound) in order to determine the percentage of GSK3β, inhibition. The IC50 value, i.e. the concentration (M) of the test compound at which 50% of GSK3, is inhibited, was calculated from the dose response curve obtained by performing the above-described GSK3β assay in the presence of different amounts of the test compound.
Table 5 lists pIC50 values (-log IC50 (M)) obtained in the above-described test for the present compounds.
TABLE 5
Comp. No. pIC50
22 5.74
24 5.36
25 5.72
26 5.81
2 6.28
17 5.30
20 5.44
6 7.01
4 5.53
33 7.11

Claims (8)

1. A method for treating, in a warm blooded animal in need of such treatment, a disease selected from the group consisting of diabetes, Alzheimer's disease and neuropathic pain,
comprising, administering to said animal a therapeutically effective amount of a compound of formula I:
Figure US07514445-20090407-C00080
 a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein
the moiety
Figure US07514445-20090407-C00081
 represents a radical of formula
Figure US07514445-20090407-C00082
R1 is hydrogen; aryl formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl;
X is —NR1—;—NH—NH—; —N—N—; —O—; —C(═O)—; —C(═S)—; —O—C(═O)—; —C(═O)—O—; —O—C(═O)—C1-6alkyl-; —C(═O)—O—C1-6alkyl-; —O—C1-6alkyl-C(═O)—; —C(═O)—C1-6alkyl-O—; —O—C(═O)—NR1—; —NR1—C(═O)—O—; —O—C(═O)—C(═O)—; —C(═O)—NR1—, —NR1—C(═O)—; —C(═S)—NR1—, —NR1—C(═S)—; —NR1—C(═O)—NR1—; —NR1—C(═)S—NR1—; —NR1—S(═O)—NR1; NR1—S(═O)2—NR1—; —C1-6alkyl-C(═O)—NR1—; —O—C1-6alkyl-C(═O)—NR1—; —C1-6alkyl-O—C(═O)—NR1—; —C 1-6alkyl-; —O—C1-6alkyl-; —C1-6alkyl-O—; —NR1—C1-6alkyl-; —C1-6alkyl-NR1—; —NR1—C1-6alkyl-NR1—; —NR1—C1-6alkyl-C3-7cycloalkyl-; —C2-6alkenyl-; —C2-6alkynyl-; —O—C2-6alkenyl-; —C2-6alkenyl-O—; —NR1—C2-6alkenyl-; —C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-NR1—; —NR1—C2-6alkenyl-C3-7cycloalkyl-; —O—C2-6alkynyl-; —C2-6alkynyl-O—; —NR1—C2-6alkynyl-; —C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-NR1—; —NR1—C2-6alkynyl-C3-7cycloalkyl-; —O—C1-6alkyl-O—; —O—C2-6alkenyl-O—; —O—C2-6alkynyl-O—; —CHOH—; —S—; —S(═O)—; —S(═O)2—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —S—C1-6alkyl-; —C1-6alkyl-S—; —S—S2-6alkenyl-; —C2-6alkenyl-S—; —S—C2-6alkynyl-; —C2-6alkynyl-S—; —O—C1-6alkyl-S(═O)2— or a direct bond;
Z is a direct bond, —O—; —S—; —C(═O)—; —C(═O)—O—; —O—C(═O)—; —C(═S)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1C(═O)—O—; —NR1—C(═S)—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —NR1—(C═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)═NR1—; —NR1—S(═O)2—NR1—;
R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from —S; —O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C3-7cycloalkyl; R5R6N—C1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
R3 is hydrogen; halo; C1-6alkyl; cyano; or polyhaloC1-6alkyl;
R4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—;R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2NR19—Y1—;
R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y1—R8, —Y1—NR9R10, or
R5 and R6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14, or each of said heterocycles may optionally be fused with a benzene ring, said benzene ring being optionally substituted with one or more substituents selected from R12, R13 and R14;
R7 is C1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino or polyhaloC1-6alkyl;
R8 is C1-6alkyl; C2-6alkenyl; C2-6alkynyl; a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
R9, R10 and R11 each independently are hydrogen or R8, or
any two of R9, R10 and R11 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
R12, R13 and R14 each independently are hydrogen; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R15R16N—S(═O)—; R15R16N—S(═O)2—; R17R18N—Y1—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2NR19—Y1—; oxo, or
any two of R12, R13 and R14 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered carbo—or heterocycle or an aromatic 4 to 8 membered monocyclic carbo—or heterocycle together with the atoms to which they are attached, or
any two of R12, R13 and R14 may together be —O—(CH2)r—O— thereby forming a saturated, partially saturated or aromatic monocyclic 4 to 8 membered carbo or heterocycle together with the atoms to which they are attached;
R15 is C1-6alkyl, a monocyclic, bicyclic or tricyclic saturated heterocycle; C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle;
R16, R17, R18 and R19 each independently are hydrogen or R15, or
R17 and R18, or R15 and R19 may together be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14; or
R17 and R18 together with R16 may be C1-6alkanediyl or C2-6alkenediyl thereby forming a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle together with the nitrogen atoms to which they are attached, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14;
R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;
R21 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said carbocycles or heterocycles representing R21 may optionally be substituted with one or more substituents selected from R12, R13 and R14;
Y1a is —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4, —Y3—C(═S)—Y4, —Y3—O—Y4—, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
Y1 or Y2 each independently are a direct bond, —Y3—S(═O)—Y4—; —Y3—S(═O)2—Y4—, —Y3—C(═O)—Y4—, —Y3—C(═S)—Y4, —Y3—O—Y4, —Y3—S—Y4—, —Y3—O—C(═O)—Y4— or —Y3—C(═O)—O—Y4—;
Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl;
n is 1 or 2;
m is 1 or 2;
p is 1 or 2;
r is 1 to 5;
s is 1 to 3;
aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy;
provided that —X—R2 and/or R3 is other than hydrogen; and
provided that
-Z—R4 is other than
Figure US07514445-20090407-C00083
 wherein Rx is hydrogen, aryl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; Ry is halo, C1-6alkyl, cyano, aminocarbonyl, nitro, trihalomethyl, trihalomethyloxy or C1-6alkyl substituted with cyano or aminocarbonyl; Rz is hydroxyl, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy or C1-6alkyl substituted with cyano or aminocarbonyl; and n′ is 0, 1, 2 or 3; and
provided that
-Z—R4 is other than C1-6alkyl substituted with indolyl which may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxyl, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, C1-6alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C1-6alkylcarbonyl.
2. The method according to claim 1 wherein
Z is a direct bond, —O—; —O—C1-6alkyl-; —C(═O)—; —C(═)—O—; —O—C(═O)—; —C(═S)—; —S(═O)—; —S(═O)2—; —NR1—; —NR1—C(═O)—; —O—C(═O)—NR1—; —NR1C(═O)—O—; —NR1—C(═S)—; —S(═O)—NR1—; —S(═O)2—NR1—; —NR1—S(═O)—; —NR1—S(═O)2—; —NR1—(C═O)—NR1—; —NR1—C(═S)—NR1—; —NR1—S(═O)—NR1—; —NR1—S(═O)2—NR1—;
R2is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, R20, each of said groups representing R2 may optionally be substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6N—C1-6alkyl; R5R6N—C3-7cycloalkyl; R5R6N—C1-6alkyloxy; R5aR6aN—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
R4 is tetrahydrofuranyl, dihydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, pyrimidinyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, triazinyl, morpholinyl, dioxolanyl or dioxanyl, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—;
R5a and R6a each independently are hydrogen, C1-6alkyl; C2-6alkenyl or C2-6alkynyl, each of said groups representing R5a and R6a may optionally be substituted with one or more substituents selected from R12, R13 and R14.
3. The method according to claim 1 wherein R4 is a 5-membered aromatic heterocycle optionally being substituted where possible with one or more substituents each independently being selected from ═S; ═O; R15; hydroxy; halo; nitro; cyano; R15—O—; SH; R15—S—; formyl; carboxyl; R15—C(═O)—; R15—O—C(═O)—; R15—C(═O)—O—; R15—O—C(═O)—O—; —SO3H; R15—S(═O)—; R15—S(═O)2—; R5R6N; R5R6NC1-6alkyl; R5R6NC3-7cycloalkyl; R5R6NC1-6alkyloxy; R5R6N—C(═O)—; R5R6N—C(═S)—; R5R6N—C(═O)—NH—; R5R6N—C(═S)—NH—; R5R6N—S(═O)n—; R5R6N—S(═O)n—NH—; R15—C(═S)—; R15—C(═O)—NH—; R15—O—C(═O)—NH—; R15—S(═O)n—NH—; R15—O—S(═O)n—NH—; R15—C(═S)—NH—; R15—O—C(═S)—NH—; R17R18N—Y1a—; R17R18N—Y2—NR16—Y1—; R15—Y2—NR19—Y1—; H—Y2—NR19—Y1—.
4. The method according to claim 3 wherein Z is a direct bond.
5. The method according to claim 1 wherein the compound is N2-(1H-indazol-5-yl)-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine; a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
6. The method according to claim 1 wherein the compound is N2-(6-morpholinyl-4-yl-pyridin-3-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(3H-benzimidazol-5-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-indazol-6-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(5-bromo-pyridin-2-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(6-methoxy-pyridin-3-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-benzothiazol-6-yl-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-indazol-5-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-benzotriazol-5-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-benzo[1,3]dioxol-5-yl-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(6-chloro-pyridin-3-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-(1H-indol-5-yl)-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; N2-quinolin-6-yl-N4-(2,4,6-trimethyl-phenyl)-2,4-pyrimidinediamine; a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
7. The method according to claim 1 wherein
X is a direct bond, —O— or —O—C1-6alkyl-;
Z is a direct bond, —NR1— or —C(═O)—;
R2 is hydrogen, or R20,
R4 is a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle or a monocyclic, bicyclic or tricyclic aromatic heterocycle, each of said heterocycles optionally being substituted where possible with one or more substituents each independently being selected from R15; R15—O—; R15—C(═O)—; or halo;
R20 is a monocyclic, bicyclic or tricyclic aromatic carbocycle;
s is 1 to 3.
8. The method according to claim 1 wherein the animal is a human.
US10/493,452 2001-11-01 2002-10-29 Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) Active 2024-05-20 US7514445B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP012041968 2001-11-01
EP01204196 2001-11-01
PCT/EP2002/012077 WO2003037891A1 (en) 2001-11-01 2002-10-29 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)

Publications (2)

Publication Number Publication Date
US20050004125A1 US20050004125A1 (en) 2005-01-06
US7514445B2 true US7514445B2 (en) 2009-04-07

Family

ID=8181177

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/493,452 Active 2024-05-20 US7514445B2 (en) 2001-11-01 2002-10-29 Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)

Country Status (16)

Country Link
US (1) US7514445B2 (en)
EP (1) EP1448556A1 (en)
JP (1) JP2005507423A (en)
KR (1) KR20040048920A (en)
CN (1) CN100491371C (en)
AU (1) AU2002363176B2 (en)
BR (1) BR0213792A (en)
CA (1) CA2463822A1 (en)
EA (2) EA010859B1 (en)
HU (1) HUP0402106A3 (en)
IL (1) IL161662A0 (en)
MX (1) MXPA04004178A (en)
NO (1) NO20041911L (en)
NZ (1) NZ531853A (en)
PL (1) PL369259A1 (en)
WO (1) WO2003037891A1 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080171878A1 (en) * 2005-05-26 2008-07-17 Didier Philippe Robert Schils Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile
US20090227586A1 (en) * 2006-06-15 2009-09-10 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10041047B2 (en) 2013-03-14 2018-08-07 Massachusetts Institute Of Technology Compositions and methods for epithelial stem cell expansion and culture
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11033546B2 (en) 2016-03-02 2021-06-15 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: I
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11160868B2 (en) 2016-03-02 2021-11-02 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490354A1 (en) 2002-03-09 2004-12-29 Astrazeneca AB 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
RS20050363A (en) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
DE602004021558D1 (en) * 2003-01-17 2009-07-30 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005068437A1 (en) * 2004-01-16 2005-07-28 Novartis Ag 2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP2007531753A (en) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Non-imidazole heterocyclic compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP5097539B2 (en) 2004-05-07 2012-12-12 アムジエン・インコーポレーテツド Protein kinase modulators and methods of use
KR20070027723A (en) 2004-06-28 2007-03-09 알타나 파마 아게 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
GB0416699D0 (en) * 2004-07-27 2004-09-01 Prometic Biosciences Ltd Prion protein ligands and methods of use
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP1899308B1 (en) 2005-06-10 2012-11-07 ProMetic BioSciences Limited Triazines as protein binding ligands
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20080214560A1 (en) * 2005-10-03 2008-09-04 Astrazeneca Ab Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
AR058073A1 (en) * 2005-10-03 2008-01-23 Astrazeneca Ab IMIDAZOL 5-IL-PYRIMIDINE DERIVATIVES, OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7777031B2 (en) 2006-05-30 2010-08-17 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
EP2032543A1 (en) 2006-06-15 2009-03-11 Boehringer Ingelheim International GmbH 2-anilino-4-aminoalkyleneaminopyrimidines
JP2010502722A (en) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド Combinations containing 4-acylaminopyridine derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2778155A1 (en) * 2007-01-31 2014-09-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
RU2009143753A (en) * 2007-04-27 2011-06-10 Астразенека Аб (Se) DERIVATIVES N '- (PHENYL) -N- (MORPHOLIN-4-IL-PYRIDIN-2-IL) -PYRIMIDIN-2, 4-IDIAMINE AS ERNB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATED CONDITIONS
AR066613A1 (en) * 2007-05-16 2009-09-02 Bayer Cropscience Sa FUNGICIDE DERIVATIVES OF FENIL-PIRIMIDINIL-AMINO
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc Heterocyclic compounds and uses thereof
JP5600063B2 (en) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド Heteroaryl compounds and uses thereof
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CN101902912A (en) * 2007-11-06 2010-12-01 纳幕尔杜邦公司 Fungicidal amines
KR101546712B1 (en) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. Cycloalkyloxy- and heterocycloalky-loxypyridine compounds as modulators of the histamine h3 receptor
AR069802A1 (en) * 2007-12-20 2010-02-17 Astrazeneca Ab CARBAMOIL COMPOUNDS AS DGAT1 190 INHIBITORS
WO2009107391A1 (en) * 2008-02-27 2009-09-03 武田薬品工業株式会社 Compound having 6-membered aromatic ring
EP3210609A1 (en) 2008-05-21 2017-08-30 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009257434B2 (en) * 2008-06-12 2014-12-11 Janssen Pharmaceutica Nv Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
ES2402087T3 (en) 2008-07-23 2013-04-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridine Kinase Inhibitors
MX2011000837A (en) 2008-07-23 2011-04-05 Vertex Pharma Tri-cyclic pyrazolopyridine kinase inhibitors.
EP2313372B1 (en) * 2008-08-06 2013-04-10 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102459252A (en) 2009-04-15 2012-05-16 阿斯利康(瑞典)有限公司 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
CN102459259A (en) 2009-05-06 2012-05-16 沃泰克斯药物股份有限公司 Pyrazolopyridines
JP5781077B2 (en) * 2009-09-22 2015-09-16 ニューロナセント インコーポレイテッド Methods and pharmaceutical compositions for treating Down syndrome
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2012008641A (en) 2010-01-27 2012-11-23 Vertex Pharma Pyrazolopyrazine kinase inhibitors.
CA2787363A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
KR101668514B1 (en) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
BR112013027734A2 (en) 2011-05-04 2017-08-08 Ariad Pharma Inc compounds for inhibition of cell proliferation in egfr-driven cancers, method and pharmaceutical composition
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN104994848A (en) 2013-02-22 2015-10-21 默沙东公司 Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MX2017010673A (en) 2015-02-20 2018-03-21 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
US10336734B2 (en) 2015-08-02 2019-07-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
US11707493B2 (en) * 2016-05-23 2023-07-25 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
US11242326B2 (en) 2017-08-25 2022-02-08 The Board Of Trustees Of The University Of Illinois Multivalent ligand for myotonic dystrophy
CR20200590A (en) 2018-05-04 2021-04-26 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
CN110484555B (en) * 2018-05-10 2021-03-23 中国农业科学院作物科学研究所 Construction method of transgenic rice with multi-seed cluster character
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (en) 2019-10-14 2022-12-15 インサイト・コーポレイション Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
EP0337943A2 (en) 1988-04-12 1989-10-18 Ciba-Geigy Ag N-Phenyl-N-pyrimidin-2-yl-ureas with herbicidal and plant-growth regulating activity
WO1991018887A1 (en) 1990-06-06 1991-12-12 Smithkline Beecham Intercredit B.V. Diaminopyrimidine compounds
WO1995009853A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof
WO1995009851A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
EP0233461B1 (en) 1986-01-13 1996-03-20 American Cyanamid Company 4,5,6-Substituted-2-pyrimidinamines
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1997019065A1 (en) 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
WO1998018782A1 (en) 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO1998041512A1 (en) * 1997-03-14 1998-09-24 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO1999050250A1 (en) 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000027825A1 (en) 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2001012621A1 (en) 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
WO2001029009A1 (en) 1999-10-20 2001-04-26 Celltech R&D Limited 4,5-disubstituted-2-aminopyrimidines
WO2001047897A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
WO2001072745A1 (en) * 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
EP0834507B1 (en) 1996-10-01 2004-05-19 Janssen Pharmaceutica N.V. Substituted diamino-1,3,5-triazine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2269364A1 (en) * 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
EP0233461B1 (en) 1986-01-13 1996-03-20 American Cyanamid Company 4,5,6-Substituted-2-pyrimidinamines
EP0337943A2 (en) 1988-04-12 1989-10-18 Ciba-Geigy Ag N-Phenyl-N-pyrimidin-2-yl-ureas with herbicidal and plant-growth regulating activity
US4966622A (en) 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
WO1991018887A1 (en) 1990-06-06 1991-12-12 Smithkline Beecham Intercredit B.V. Diaminopyrimidine compounds
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5728708A (en) 1993-10-01 1998-03-17 Novartis Corporation Pharmacologically active pyridine derivatives and processes for the preparation thereof
WO1995009853A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof
WO1995009851A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5958935A (en) 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO1997019065A1 (en) 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
US6441053B1 (en) 1996-05-07 2002-08-27 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
EP0834507B1 (en) 1996-10-01 2004-05-19 Janssen Pharmaceutica N.V. Substituted diamino-1,3,5-triazine derivatives
WO1998018782A1 (en) 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO1998041512A1 (en) * 1997-03-14 1998-09-24 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO1999050250A1 (en) 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000027825A1 (en) 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2001012621A1 (en) 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
WO2001029009A1 (en) 1999-10-20 2001-04-26 Celltech R&D Limited 4,5-disubstituted-2-aminopyrimidines
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
WO2001047897A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
WO2001072745A1 (en) * 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996. *
Cohen et al., Nature Reviews/Molecular Biology 2: 769-776, 2001. *
Hers, I. et al., "The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity," FEBS Letters, 1999, 460, 433-436.
Jope et al., Trends in Biochemical Sciences, 20(2): 95-102, 2004. *
Patel et al. Biochem. Soc. Trans. 32(5), 803-808,2004. *
Smith, D. G. et al., "3-Anilino-4-arylmaleimides: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3)," Bioorganic & Medicinal Chemistry Letters, 2001, 11, 635-639.

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101752B2 (en) * 2005-05-26 2012-01-24 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
US8618291B2 (en) 2005-05-26 2013-12-31 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-OXO-2-pyrimidinyl)amino]benzonitrile
US20080171878A1 (en) * 2005-05-26 2008-07-17 Didier Philippe Robert Schils Process for Preparing 4-[(1,6-Dihydro-6-Oxo-2-Pyrimidinyl)Amino]Benzonitrile
US20090227586A1 (en) * 2006-06-15 2009-09-10 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines
US8354407B2 (en) * 2006-06-15 2013-01-15 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9987276B2 (en) 2008-06-27 2018-06-05 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US10010548B2 (en) 2008-06-27 2018-07-03 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9296737B2 (en) 2008-06-27 2016-03-29 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US10828300B2 (en) 2008-06-27 2020-11-10 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US10596172B2 (en) 2008-06-27 2020-03-24 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9790228B2 (en) 2008-09-26 2017-10-17 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US11096942B2 (en) 2010-11-01 2021-08-24 Celgene Car Llc Heterocyclic compounds and uses thereof
US9867824B2 (en) 2010-11-01 2018-01-16 Celgene Car Llc Heterocyclic compounds and uses thereof
US10081606B2 (en) 2010-11-01 2018-09-25 Celgene Car Llc Heteroaryl compounds and uses thereof
US9765038B2 (en) 2010-11-01 2017-09-19 Celgene Car Llc Heteroaryl compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9375431B2 (en) 2010-11-01 2016-06-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10434101B2 (en) 2010-11-01 2019-10-08 Celgene Car Llc Heterocyclic compounds and uses thereof
US9868723B2 (en) 2010-11-10 2018-01-16 Celgene Car Llc Mutant-selective EGFR inhibitors and uses thereof
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9605003B2 (en) 2011-07-19 2017-03-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9539255B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US11292772B2 (en) 2012-03-15 2022-04-05 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10570099B2 (en) 2012-03-15 2020-02-25 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9540335B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US10946016B2 (en) 2012-03-15 2021-03-16 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10004741B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10005738B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9549927B2 (en) 2012-12-21 2017-01-24 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9980964B2 (en) 2013-02-08 2018-05-29 Celgene Car Llc ERK inhibitors and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9796700B2 (en) 2013-02-08 2017-10-24 Celgene Car Llc ERK inhibitors and uses thereof
US9504686B2 (en) 2013-02-08 2016-11-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10954490B2 (en) 2013-03-14 2021-03-23 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
US10041046B2 (en) 2013-03-14 2018-08-07 Massachusetts Institute Of Technology Compositions and methods for epithelial stem cell expansion and culture
US10041047B2 (en) 2013-03-14 2018-08-07 Massachusetts Institute Of Technology Compositions and methods for epithelial stem cell expansion and culture
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US11541059B2 (en) 2014-03-19 2023-01-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10675286B2 (en) 2014-03-19 2020-06-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10202364B2 (en) 2014-08-13 2019-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
US11369607B2 (en) 2014-09-03 2022-06-28 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US10941162B2 (en) 2014-10-03 2021-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11939333B2 (en) 2015-09-14 2024-03-26 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11247995B2 (en) 2015-09-14 2022-02-15 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11160868B2 (en) 2016-03-02 2021-11-02 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US11033546B2 (en) 2016-03-02 2021-06-15 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: I
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Also Published As

Publication number Publication date
KR20040048920A (en) 2004-06-10
AU2002363176B2 (en) 2008-09-25
US20050004125A1 (en) 2005-01-06
NZ531853A (en) 2006-02-24
IL161662A0 (en) 2004-09-27
NO20041911L (en) 2004-05-10
EA200400617A1 (en) 2004-10-28
WO2003037891A8 (en) 2003-09-04
CN1582285A (en) 2005-02-16
HUP0402106A3 (en) 2009-07-28
EA200600652A1 (en) 2008-02-28
WO2003037891A1 (en) 2003-05-08
EA007298B1 (en) 2006-08-25
HUP0402106A2 (en) 2005-02-28
BR0213792A (en) 2004-12-07
EP1448556A1 (en) 2004-08-25
CA2463822A1 (en) 2003-05-08
CN100491371C (en) 2009-05-27
JP2005507423A (en) 2005-03-17
EA010859B1 (en) 2008-12-30
MXPA04004178A (en) 2004-09-06
PL369259A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
US7514445B2 (en) Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
EP1442024B1 (en) AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS
US7183288B2 (en) Amide derivatives as glycogen synthase kinase 3-β inhibitors
AU2002363176A1 (en) Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
AU2002363177A1 (en) Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors
AU2002363174A1 (en) Amide derivatives as glycogen synthase kinase 3-beta inhibitors
DE69919707T2 (en) GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
DE60314603T2 (en) COMPOSITIONS NECESSARY AS PROTEIN KINASE INHIBITORS
JP2007513172A (en) Heterocyclic protein kinase inhibitors and uses thereof
RU2718915C2 (en) Pyrimidine derivatives as kinase inhibitors and therapeutic applications thereof
US20210213006A1 (en) Methods of treating neurodegenerative diseases
EP3853225B1 (en) N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer
US10195201B2 (en) Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
NZ543748A (en) Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors)
RU2779534C2 (en) Benzimidazole derivatives, methods for their production and use
JP2018531266A (en) Pyridone derivatives and their use as kinase inhibitors
JP2018531266A6 (en) Pyridone derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FREYNE, EDDY J. E.;BUIJNSTERS, PETER J. J. A.;KOYMANS, LUCIEN M. H.;AND OTHERS;REEL/FRAME:019183/0566

Effective date: 20050302

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12